var title_f29_38_30304="JEB non-Herlitz adults 2";
var content_f29_38_30304=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Junctional epidermolysis bullosa (JEB) non-Herlitz in adults",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 318px; height: 447px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tense blisters, nonhealing erosions, partly hemorrhagic crusts, and skin atrophy with stellate scars predominant in adults with JEB non-Herlitz.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_38_30304=[""].join("\n");
var outline_f29_38_30304=null;
var title_f29_38_30305="Flexion deflexion vertex";
var content_f29_38_30305=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Presentation, breech, cranial diameters",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 228px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Importance of cranial flexion is emphasized by noting the increased diameters presented to the birth canal with progressive deflection. A) Flexed head. B) Military position. C, D) Progressive deflection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: LifeART, Obstetrics &amp; Gynecology. Copyright &copy;2009 Lippincott Williams &amp; Wilkins. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_38_30305=[""].join("\n");
var outline_f29_38_30305=null;
var title_f29_38_30306="TEE mitral valve aneurysm from endocarditis";
var content_f29_38_30306=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/65848/teemvane_conv.mp4?title=TEE+mitral+valve+aneurysm+from+endocarditis\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transesophageal echocardiogram (TEE) showing a mitral valve aneurysm associated with endocarditis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 277px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The transesophageal echocardiogram shows vegetations of the aortic valve leaflets due to endocarditis and an abscess of the mitral valve annulus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_38_30306=[""].join("\n");
var outline_f29_38_30306=null;
var title_f29_38_30307="Patient information: Aortic dissection (The Basics)";
var content_f29_38_30307=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/85372\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/23/41329\">",
"         Anatomy of the aorta",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/17/42260\">",
"          Endovascular stent graft for an aortic dissection",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?21/39/22130\">",
"         Patient information: Abdominal aortic aneurysm (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/61/25554\">",
"         Patient information: Advance directives (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/34/21027\">",
"         Patient information: Chest pain (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/13/24787\">",
"         Patient information: Echocardiogram (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/53/10068\">",
"         Patient information: Heart attack (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/12/17601\">",
"         Patient information: Heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/58/34722\">",
"         Patient information: High blood pressure in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/11/25778\">",
"         Patient information: Marfan syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/40/23171\">",
"         Patient information: Medicines for high blood pressure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/55/24435\">",
"         Patient information: Stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/5/36946\">",
"         Patient information: Syncope (fainting) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?33/62/34787\">",
"         Patient information: Abdominal aortic aneurysm (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/9/43157\">",
"         Patient information: Chest pain (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/16/40195\">",
"         Patient information: Heart attack (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/5/33877\">",
"         Patient information: Heart failure (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/54/33635\">",
"         Patient information: High blood pressure in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/37/38484\">",
"         Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?4/9/4245\">",
"         Patient information: Syncope (fainting) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Aortic dissection (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/aortic-dissection-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H202680243\">",
"      <span class=\"h1\">",
"       What is an aortic dissection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An aortic dissection is a condition that causes sudden and severe pain in the chest, back, or belly. It involves the aorta, which is the main blood vessel that comes out of the heart and carries blood to the body (",
"      <a class=\"graphic graphic_figure graphicRef74006 \" href=\"UTD.htm?40/23/41329\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      The aorta has different parts. The part of the aorta that comes out of the heart and heads toward the neck is called the &ldquo;ascending aorta.&rdquo; From there, the aorta curves around (this is called the &ldquo;aortic arch&rdquo;) and heads down toward the belly. The part of the aorta that heads toward the belly is called the &ldquo;descending aorta&rdquo; (",
"      <a class=\"graphic graphic_figure graphicRef74006 \" href=\"UTD.htm?40/23/41329\">",
"       figure 1",
"      </a>",
"      ). An aortic dissection can happen in either the ascending or descending aorta.",
"     </p>",
"     <p>",
"      In an aortic dissection, the inner wall of the aorta gets damaged or tears. Most often, the tear is in the first part of the descending aorta. Because of this:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood gets stuck in the damaged part of the wall &ndash; As a result, the body&rsquo;s organs might not get enough blood. This can lead to problems such as a heart attack, brain damage, kidney damage, intestinal problems, or not enough blood flowing to the legs or arms.",
"       </li>",
"       <li>",
"        The wall of the aorta can burst open &ndash; This causes lots of internal bleeding and is an emergency.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      An aortic dissection is a serious condition. Many people who have an ascending aortic dissection or a severe descending aortic dissection don&rsquo;t survive, even with treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H202680292\">",
"      <span class=\"h1\">",
"       What are the symptoms of an aortic dissection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An aortic dissection causes sudden, severe, sharp, and &ldquo;tearing&rdquo; pain in the chest, back, or belly.",
"     </p>",
"     <p>",
"      People can have other symptoms, too, depending on the problems caused by the aortic dissection. For example, people might faint, or have trouble talking or moving part of the body (if blood flow to the brain is affected). Or the arms or legs can feel cool to the touch (if blood flow to the arms or legs is affected).",
"     </p>",
"     <p>",
"      <strong>",
"       Is there a test for an aortic dissection?",
"      </strong>",
"      &ndash; Yes. Tests that show the doctor that there is a tear in the aorta include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A chest X-ray &ndash; This does not show the tear, but can show whether the aorta is bigger than normal.",
"       </li>",
"       <li>",
"        An echocardiogram (also called an &ldquo;echo&rdquo;) &ndash; This test uses sound waves to create a picture of the heart and aorta. There are different ways a doctor can do an echo. For a &ldquo;transthoracic echo,&rdquo; the doctor puts a thick wand on a person&rsquo;s chest and moves it around. For a &ldquo;transesophageal echo,&rdquo; the doctor puts a tube with a wand on the end into a person&rsquo;s mouth and down into the esophagus. The doctor presses the wand against the esophagus wall to create images of the heart and aorta. Doctors usually do a transesophageal echo to look for an aortic dissection.",
"       </li>",
"       <li>",
"        Other imaging tests, such as a CT or MRI scan &ndash; Imaging tests create pictures of the inside of the body.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H202680307\">",
"      <span class=\"h1\">",
"       How is an aortic dissection treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on a person&rsquo;s symptoms and whether the aortic dissection is in the ascending or descending aorta.",
"     </p>",
"     <p>",
"      An aortic dissection in the ascending aorta is treated right away with surgery to fix the aorta. That&rsquo;s because this type of aortic dissection is an emergency.",
"     </p>",
"     <p>",
"      An aortic dissection in the descending aorta is treated in different ways, depending on how serious the condition is. If a person&rsquo;s condition is not so serious, he or she will be treated with:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Strong pain-relieving medicines",
"       </li>",
"       <li>",
"        Medicines to lower the blood pressure or slow down the heartbeat",
"       </li>",
"       <li>",
"        A breathing tube (if he or she is having trouble breathing) &ndash; A breathing tube is a tube that goes down the throat and into the lungs. The other end is attached to a machine that helps with breathing.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If the descending aortic dissection is serious, people usually need surgery or a procedure to fix the aorta. This is done in 2 main ways:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        &ldquo;Open&rdquo; surgery &ndash; In this surgery, the doctor cuts the chest open and replaces the damaged aorta with a tube called a &ldquo;graft.&rdquo; This tube is made from man-made materials. It is sewn into place. Blood can flow normally through it.",
"       </li>",
"       <li>",
"        Endovascular stent graft &ndash; To fix the aorta this way, the doctor makes a cut in a blood vessel at the top of the thigh. He or she puts a folded graft in the blood vessel and threads it up to the damaged part of the aorta. Then the doctor unfolds the graft. This graft does not need to be sewn into place. Blood flows through the graft (",
"        <a class=\"graphic graphic_figure graphicRef84002 \" href=\"UTD.htm?41/17/42260\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People who have an aortic dissection also need life-long treatment. They need to:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Take 1 or more blood pressure medicines every day.",
"       </li>",
"       <li>",
"        Avoid heavy exercise.",
"       </li>",
"       <li>",
"        Get regular follow-up imaging tests to check if the dissection is getting bigger or leaking. If the aortic dissection gets worse, people might need to have surgery.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H202680345\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/34/21027?source=see_link\">",
"       Patient information: Chest pain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/39/22130?source=see_link\">",
"       Patient information: Abdominal aortic aneurysm (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=see_link\">",
"       Patient information: Heart attack (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"       Patient information: Stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/5/36946?source=see_link\">",
"       Patient information: Syncope (fainting) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=see_link\">",
"       Patient information: Heart failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=see_link\">",
"       Patient information: High blood pressure in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=see_link\">",
"       Patient information: Echocardiogram (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/40/23171?source=see_link\">",
"       Patient information: Medicines for high blood pressure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/61/25554?source=see_link\">",
"       Patient information: Advance directives (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/11/25778?source=see_link\">",
"       Patient information: Marfan syndrome (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/9/43157?source=see_link\">",
"       Patient information: Chest pain (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/62/34787?source=see_link\">",
"       Patient information: Abdominal aortic aneurysm (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"       Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?4/9/4245?source=see_link\">",
"       Patient information: Syncope (fainting) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=see_link\">",
"       Patient information: Heart failure (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=see_link\">",
"       Patient information: Heart attack (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=see_link\">",
"       Patient information: High blood pressure in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?29/38/30307?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 85372 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-194.187.108.93-69C8FD1B77-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_38_30307=[""].join("\n");
var outline_f29_38_30307=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H202680243\">",
"      What is an aortic dissection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H202680292\">",
"      What are the symptoms of an aortic dissection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H202680307\">",
"      How is an aortic dissection treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H202680345\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/85372\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/23/41329\">",
"      Anatomy of the aorta",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/17/42260\">",
"       Endovascular stent graft for an aortic dissection",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/62/34787?source=related_link\">",
"      Patient information: Abdominal aortic aneurysm (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/39/22130?source=related_link\">",
"      Patient information: Abdominal aortic aneurysm (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/61/25554?source=related_link\">",
"      Patient information: Advance directives (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/9/43157?source=related_link\">",
"      Patient information: Chest pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/34/21027?source=related_link\">",
"      Patient information: Chest pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=related_link\">",
"      Patient information: Heart attack (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=related_link\">",
"      Patient information: Heart attack (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=related_link\">",
"      Patient information: Heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=related_link\">",
"      Patient information: High blood pressure in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=related_link\">",
"      Patient information: High blood pressure in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/11/25778?source=related_link\">",
"      Patient information: Marfan syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/40/23171?source=related_link\">",
"      Patient information: Medicines for high blood pressure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=related_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/9/4245?source=related_link\">",
"      Patient information: Syncope (fainting) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/5/36946?source=related_link\">",
"      Patient information: Syncope (fainting) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_38_30308="Pneumonia in adults";
var content_f29_38_30308=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Pneumonia in adults (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?29/38/30308/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/38/30308/contributors\" id=\"au114\">",
"       Thomas J Marrie, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/38/30308/contributors\" id=\"au148\">",
"       Thomas M File, Jr, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?29/38/30308/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/38/30308/contributors\" id=\"se136\">",
"       John G Bartlett, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?29/38/30308/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/38/30308/contributors\" id=\"de1919\">",
"       Anna R Thorner, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?29/38/30308?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      PNEUMONIA OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Pneumonia is an infection of the lungs. It is a serious illness that can affect people of any age, although it is most serious in the very young, people over the age of 65, and those with underlying medical problems such as congestive heart disease, diabetes, and chronic lung disease. It is most common during the winter months, and occurs more often in smokers and men.",
"    </p>",
"    <p>",
"     This article will focus on community-acquired pneumonia (CAP), which refers to pneumonia that develops in people in the community, rather than in a hospital, nursing home, or assisted-living facility. About four million cases of CAP occur each year in the United States, and approximately 20 percent of people require hospitalization.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      LUNG FUNCTION",
"     </span>",
"    </p>",
"    <p>",
"     As we breathe, air is inhaled through the nose and mouth, and travels through the trachea and the bronchi to the bronchioles. At the end of the bronchioles, there are tiny air sacs, called alveoli. Alveoli have thin, porous walls that contain capillaries (",
"     <a class=\"graphic graphic_figure graphicRef55943 \" href=\"UTD.htm?10/3/10294\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     The mouth and respiratory tract are constantly exposed to microorganisms as air is inhaled through the nose and mouth. However, the body's defenses are usually able prevent microorganisms from entering and infecting the lungs. These defenses include the immune system, the specialized shape of the nose and pharynx, the ability to cough, and fine hair-like structures called cilia located on the bronchi. Pneumonia can develop if your defenses are not adequate or the microorganism is particularly strong.",
"    </p>",
"    <p>",
"     As microorganisms multiply, the alveoli become inflamed and accumulate fluid. These changes lead to the symptoms of pneumonia. (See",
"     <a class=\"local\" href=\"#H5\">",
"      'Pneumonia symptoms'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      HIGH-RISK GROUPS",
"     </span>",
"    </p>",
"    <p>",
"     Some groups of adults are at a greater risk of developing pneumonia. These include people who:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Are greater than 65 years old",
"      </li>",
"      <li>",
"       Are cigarette smokers",
"      </li>",
"      <li>",
"       Are malnourished due to health conditions or lack of access to food",
"      </li>",
"      <li>",
"       Have underlying lung disease, including cystic fibrosis, asthma, or chronic obstructive pulmonary disease (emphysema)",
"      </li>",
"      <li>",
"       Have other underlying medical problems, including diabetes or heart disease",
"      </li>",
"      <li>",
"       Have a weakened immune system due to HIV, organ transplant, chemotherapy, or chronic steroid use",
"      </li>",
"      <li>",
"       Have difficulty coughing due to stroke, sedating drugs or alcohol, or limited mobility",
"      </li>",
"      <li>",
"       Have had a recent viral upper respiratory tract infection including influenza",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      PNEUMONIA CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     Pneumonia can be caused by a variety of microorganisms, including viruses, bacteria, and less commonly, fungi. The most common cause of pneumonia in the United States is the bacterium Streptococcus pneumoniae, or pneumococcus.",
"    </p>",
"    <p>",
"     Viruses are estimated to be the cause of adult CAP in at least 20 percent of cases. Fungi rarely cause pneumonia in people who are generally healthy; people with a weakened immune system (those with HIV, organ transplant patients, or those on chemotherapy) are at higher risk of fungal infection. Other organisms, such as Mycoplasma, are a common cause of mild pneumonia but can occasionally cause serious disease.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      PNEUMONIA SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Common symptoms of pneumonia include shortness of breath, pain with breathing, a rapid heart and breathing rate, nausea, vomiting, diarrhea, and a cough that often produces green or yellow sputum; occasionally the sputum is rust colored. Most people have a fever (temperature greater than 100.5&ordm;F or 38&ordm;C), although elderly people have fever less often. Shaking chills (called rigors) and a change in mental status (confusion, unclear thinking) can occur.",
"    </p>",
"    <p>",
"     The characteristics of pneumonia are different than those of a more common infection, acute viral bronchitis, which does not usually cause fever and does not require treatment with an antibiotic. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/57/9106?source=see_link\">",
"      \"Patient information: Acute bronchitis in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      PNEUMONIA DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Pneumonia is usually diagnosed with a medical history and physical examination, as well as a chest x-ray. The need for further testing depends upon the severity of the illness and the person's risk of complications.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Chest x-ray",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chest x-ray and sometimes other imaging studies, such as CT scan, are used for diagnosing pneumonia when the history and physical examination also support the diagnosis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Sputum testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sputum testing requires a sample of sputum, collected from a deep cough. Culture of sputum is used to identify the bacteria that caused the pneumonia and can help determine which antibiotic is best.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1066482464\">",
"     <span class=\"h2\">",
"      Urine antigen testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Urine tests can be helpful for diagnosing pneumonia caused by two bacteria, Streptococcus pneumoniae and Legionella pneumophila. These tests are easy to perform, and provide rapid results.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Blood testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients who are hospitalized require blood testing, including a complete blood cell count (CBC) and sometimes a blood culture. A CBC measures the number of many types of blood cells, including white blood cells (WBC); these cells multiply when there is a bacterial infection. An increased number of WBCs is one indicator that a bacterial infection, including pneumonia, may be present.",
"    </p>",
"    <p>",
"     A blood culture is used to determine whether the infection has spread from the lungs into the blood stream. It involves taking a sample of blood from a vein and testing it for bacteria. &nbsp;Normally, there should be no bacteria in the bloodstream. Blood cultures are used to identify the bacteria that caused the pneumonia and to guide the choice of antibiotic. A patient's antibiotics may be changed when results of the blood or sputum cultures are completed (usually after 48 to 72 hours).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Blood oxygen measurement",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pneumonia can decrease the amount of oxygen available in the blood. As a result, a blood oxygen level is often measured by attaching a small clip to the finger or ear that uses infrared light. In those who are sicker, the oxygen level may be measured by withdrawing a sample of blood from an artery.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Bronchoscopy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients who present initially with severe pneumonia or who fail to improve or worsen during their hospitalization despite treatment with antibiotics may require further testing with bronchoscopy. In this procedure, a physician uses a thin, flexible tube with a camera to view the trachea and bronchi (the tube between the trachea and lungs). This allows them to look directly at the lungs, collect fluid samples or a biopsy (a small tissue sample), and determine whether there is an underlying cause of infection, such as a growth or inhaled foreign body. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/14/32993?source=see_link\">",
"      \"Patient information: Flexible bronchoscopy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      PNEUMONIA TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The goal of treatment for patients with CAP is to treat the infection and prevent complications. Initial treatment of CAP is based upon the organism that is likely to be causing pneumonia (called empiric treatment). Most patients improve with empiric treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Hospital versus home care",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most patients are treated for CAP at home with oral antibiotics. People who are seriously ill or are at increased risk for complications may be hospitalized. Hospital monitoring usually includes measurement of heart and breathing rate, temperature, and oxygen levels. Hospitalized patients are usually given intravenous (IV) antibiotics initially. The number of days spent in the hospital is variable, and depends upon how a person responds to treatment and if there are underlying medical problems. &nbsp;",
"    </p>",
"    <p>",
"     Some patients, including people with previous lung damage or disease, a weakened immune system, or infection in more than one lobe of the lungs (called multilobar pneumonia), may be slow to recover and require a longer hospitalization.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Antibiotic choice",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of antibiotic treatment regimens exist for treatment of CAP. The choice of which antibiotic to use is based upon several factors, including the person's underlying medical problems and the likelihood of being infected with a bacteria that is resistant to specific drugs.",
"    </p>",
"    <p>",
"     People with certain underlying medical problems and those who have used antibiotics in the past three months have a higher risk of infection with drug resistant bacteria. For all antibiotic regimens, it is important to finish the entire course of medication and take it exactly as directed.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      EXPECTED RECOVERY FROM PNEUMONIA",
"     </span>",
"    </p>",
"    <p>",
"     A person with pneumonia usually begins to improve after three to five days of antibiotic treatment. Improvement may be defined as feeling better or having fewer symptoms, such as cough and fever. Fatigue and a persistent, but milder, cough can last for up to one month, although most people are able to resume their usual activities within seven days. Patients treated in the hospital may require three weeks or more to resume normal activities.",
"    </p>",
"    <p>",
"     All patients, whether treated at home or in the hospital, should take special care of themselves during the recovery period. This includes getting adequate rest at night and taking naps during the day if needed. Patients should drink fluids to avoid becoming dehydrated; there is no specific amount of fluid recommended, but thirst is a good indicator of the need to drink more fluids. Patients should be sure to finish all of their antibiotic medication, even if they feel better after a few days.",
"    </p>",
"    <p>",
"     All patients should see a healthcare provider four to six weeks after being diagnosed with pneumonia. This visit allows the provider to be sure that the patient is feeling better and has no new problems.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      PNEUMONIA COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     Pneumonia can usually be treated successfully without leading to complications. However, complications can develop in some patients, especially those in high-risk groups.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Fluid accumulation &mdash; Fluid can develop between the covering of the lungs (pleura) and the inner lining of the chest wall; this is called a pleural effusion. If the fluid becomes infected as a result of pneumonia (called empyema), a chest tube (or less commonly, surgery) may be needed to drain the fluid.",
"      </li>",
"      <li>",
"       Abscess &mdash; A collection of pus in the area infected with pneumonia is known as an abscess. They can usually be treated with antibiotics; rarely, surgical removal is needed.",
"      </li>",
"      <li>",
"       Bacteremia &mdash; Bacteremia occurs when the pneumonia infection spreads from the lungs to the bloodstream. This is a serious complication since infection can spread quickly from the bloodstream to other organs. Bacteremia can also cause the blood pressure to be dangerously low.",
"      </li>",
"      <li>",
"       Death &mdash; Although most people recover from pneumonia, it can be fatal in some cases. The mortality rate is approximately 5 to 10 percent among patients admitted to a general medical ward, but is as high as 30 percent in patients with severe infection requiring admission to an intensive care unit.",
"       <br/>",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      WHEN TO SEEK HELP",
"     </span>",
"    </p>",
"    <p>",
"     Anyone who suspects that they have pneumonia should seek medical care as soon as possible. Pneumonia is a serious illness that can be life-threatening if not treated, especially for people who are older than 65 years, alcoholic, have underlying medical problems, or a weakened immune system.",
"    </p>",
"    <p>",
"     People with the following symptoms should see their healthcare provider promptly:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Fever and cough with phlegm that does not improve or worsens",
"      </li>",
"      <li>",
"       New shortness of breath with normal daily activities",
"      </li>",
"      <li>",
"       Chest pain with breathing",
"      </li>",
"      <li>",
"       Feeling suddenly worse after a cold or the flu",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      PREVENTION",
"     </span>",
"    </p>",
"    <p>",
"     The pneumococcal vaccine is one of the most effective ways to prevent pneumonia. The influenza (or \"flu\") vaccine is important not only for preventing influenza but also for preventing its complications, including pneumonia. These vaccines are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14225?source=see_link\">",
"      \"Patient information: Pneumonia prevention (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/12/39105?source=see_link\">",
"      \"Patient information: Influenza prevention (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Smoking cessation is another important way to prevent pneumonia.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Infection control",
"     </span>",
"     &nbsp;&mdash;&nbsp;Infection control measures can help to prevent the spread of any type of infection, including pneumonia. Infection control is most commonly practiced in healthcare settings, but is useful in the community as well. Simple practices such as frequent hand washing with soap and water or alcohol-based hand rubs can be effective.",
"    </p>",
"    <p>",
"     Because pneumonia is spread by contact with infected respiratory secretions, people with pneumonia should limit face-to-face contact with uninfected family and friends. The mouth and nose should be covered while coughing or sneezing, and tissues should be disposed of immediately.",
"     <span class=\"nowrap\">",
"      Sneezing/coughing",
"     </span>",
"     into the sleeve of one's clothing (at the inner elbow) is another means of containing sprays of saliva and secretions and has the advantage of not contaminating the hands.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804432864\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15696542\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=see_link\">",
"      Patient information: Pneumonia in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/29/12754?source=see_link\">",
"      Patient information: Community-acquired pneumonia in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/1/19474?source=see_link\">",
"      Patient information: Hospital-acquired pneumonia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/34/13858?source=see_link\">",
"      Patient information: Aspiration pneumonia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/24/7554?source=see_link\">",
"      Patient information: Pneumocystis pneumonia (PCP) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/46/6883?source=see_link\">",
"      Patient information: Shortness of breath (dyspnea) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/0/43011?source=see_link\">",
"      Patient information: Cough in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/14/4322?source=see_link\">",
"      Patient information: Adult respiratory distress syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/45/4819?source=see_link\">",
"      Patient information: Pleuritic chest pain (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/53/27475?source=see_link\">",
"      Patient information: Paraplegia and quadriplegia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/53/41810?source=see_link\">",
"      Patient information: Rib fractures in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/52/20292?source=see_link\">",
"      Patient information: Diabetes and infections (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/9/14483?source=see_link\">",
"      Patient information: Interstitial lung disease (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15696550\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/57/9106?source=see_link\">",
"      Patient information: Acute bronchitis in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/14/32993?source=see_link\">",
"      Patient information: Flexible bronchoscopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14225?source=see_link\">",
"      Patient information: Pneumonia prevention (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31017?source=see_link\">",
"      Aspiration pneumonia in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15449?source=see_link\">",
"      Bacterial pulmonary infections in HIV-infected patients",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38199?source=see_link\">",
"      Clinical manifestations and diagnosis of Legionella infection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7577?source=see_link\">",
"      Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=see_link\">",
"      Clinical presentation and diagnosis of ventilator-associated pneumonia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38473?source=see_link\">",
"      Community-acquired pneumonia in adults: Risk stratification and the decision to admit",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32680?source=see_link\">",
"      Epidemiology and pathogenesis of Legionella infection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=see_link\">",
"      Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12183?source=see_link\">",
"      Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/5/3162?source=see_link\">",
"      Mycoplasma pneumoniae infection in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23945?source=see_link\">",
"      Nonresolving pneumonia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/4/13386?source=see_link\">",
"      Pneumococcal pneumonia in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7270?source=see_link\">",
"      Pneumonia caused by Chlamydophila (Chlamydia) pneumoniae in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31494?source=see_link\">",
"      Pseudomonas aeruginosa pneumonia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13433?source=see_link\">",
"      Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17591?source=see_link\">",
"      Sputum cultures for the evaluation of bacterial pneumonia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24969?source=see_link\">",
"      Treatment of community-acquired pneumonia in adults in the outpatient setting",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=see_link\">",
"      Treatment of community-acquired pneumonia in adults who require hospitalization",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=see_link\">",
"      Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39528?source=see_link\">",
"      Treatment of Pseudomonas aeruginosa infections",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/000145.htm\">",
"      www.nlm.nih.gov/medlineplus/ency/article/000145.htm",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Allergy and Infectious Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     (",
"     <a class=\"external\" href=\"file://www.niaid.nih.gov/\">",
"      www.niaid.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Lung Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.lungusa.org/\">",
"      www.lungusa.org",
"     </a>",
"     , click on \"Diseases A to Z\", then click on \"P\")",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Canadian Lung Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.lung.ca/pneumonia\">",
"      www.lung.ca/pneumonia",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?29/38/30308/abstract/1,2\">",
"      1,2",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 3, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?29/38/30308?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30308/abstract/1\">",
"      Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30308/abstract/2\">",
"      File TM. Community-acquired pneumonia. Lancet 2003; 362:1991.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f29_38_30308=[""].join("\n");
var outline_f29_38_30308=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           PNEUMONIA OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           LUNG FUNCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           HIGH-RISK GROUPS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           PNEUMONIA CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           PNEUMONIA SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           PNEUMONIA DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           PNEUMONIA TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           EXPECTED RECOVERY FROM PNEUMONIA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           PNEUMONIA COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           WHEN TO SEEK HELP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/3/10294\" title=\"figure 1\">",
"           Pneumonia anatomy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f29_38_30309="Costochondritis PI";
var content_f29_38_30309=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F72179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F72179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 571px\">",
"   <div class=\"ttl\">",
"    Costochrondritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 551px; height: 604px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Costochondritis causes pain and tenderness in the costosternal joints.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_38_30309=[""].join("\n");
var outline_f29_38_30309=null;
var title_f29_38_30310="Minimally invasive aortic and mitral valve surgery";
var content_f29_38_30310=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Minimally invasive aortic and mitral valve surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/38/30310/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/38/30310/contributors\">",
"     Gabriel S Aldea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/38/30310/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/38/30310/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/38/30310/contributors\">",
"     Edward Verrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/38/30310/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/38/30310/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/38/30310/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less invasive surgical techniques using laparoscopic and robotic approaches through smaller \"key hole\" incisions with specialized instruments have been applied to many abdominal, urologic, and gynecologic procedures. These alternative approaches are safe and effective, resulting in a reduction in patient discomfort and hospital length of stay and cost.",
"   </p>",
"   <p>",
"    The application of similar techniques to open cardiac surgery are being explored and the use of these procedures for aortic and mitral valve surgery will be reviewed here. Transcatheter approaches for aortic and mitral valve disease and minimally invasive approaches to coronary artery bypass graft surgery are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37031?source=see_link\">",
"     \"Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/16/44296?source=see_link\">",
"     \"Minimally invasive coronary artery bypass graft surgery: Definitions and technical issues\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/29/34264?source=see_link\">",
"     \"Transcatheter aortic valve replacement\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MINIMALLY INVASIVE CARDIAC VALVULAR SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most surgical approaches to valve surgery require cardiopulmonary bypass (CPB) and cardioplegic arrest, ie, open cardiac procedures, although percutaneous aortic and pulmonic valve techniques are available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39411?source=see_link\">",
"     \"Percutaneous aortic valvotomy\"",
"    </a>",
"    .) New approaches to aortic and mitral valve surgery during cardiopulmonary bypass (CPB) have explored the use of alternative incisions to median sternotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30310/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Cannulation can be performed directly into the ascending aorta and right atrium through a limited (10 cm) incision [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30310/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatively, access for cannulation for CPB can be obtained through the axillary artery (which is frequently spared from extensive atheromatous disease) or a groin incision using the common femoral vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30310/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. Retrograde instrumentation and perfusion through the common femoral vessels is only possible and safe in patients who do not have significant peripheral vascular disease. Thus, careful patient selection, thorough evaluation of the vessels with computed tomography, and magnetic resonance angiography are recommended. Aortic cross clamping for the purpose of cardioplegic diastolic arrest can be performed directly through the incision or, alternatively, with an endoluminal specially designed balloon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Aortic valve surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minimally invasive aortic valve replacement for aortic stenosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aortic regurgitation can be performed through one of several approaches:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A transsternal incision made at the level of the manubrium through the third or fourth right intercostal space (J incision)",
"     </li>",
"     <li>",
"      A right parasternal incision, removing the cartilaginous portions of the second or third ribs",
"     </li>",
"     <li>",
"      A superior partial sternal split approach (T incision)",
"     </li>",
"     <li>",
"      A right second intercostal anterior thoracotomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Surgery on the aortic valve itself uses conventional instruments and techniques. The results for isolated aortic valve surgery should, therefore, be similar to those with conventional techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30310/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. One study randomly assigned 120 patients (109 with aortic stenosis and 11 with aortic regurgitation) to minimally invasive or conventional surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30310/abstract/6\">",
"     6",
"    </a>",
"    ]. Compared to conventional surgery, patients undergoing minimally invasive surgery were extubated earlier, had less blood loss, required less postoperative analgesia, and had a lower incidence of pericardial effusion and supraventricular tachyarrhythmias; the overall survival rate at 294 days was equivalent for the two procedures (95 versus 97 percent for conventional surgery).",
"   </p>",
"   <p>",
"    However, other studies have noted some concerns with minimally invasive aortic valve surgery. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Partial, compared to complete sternotomy, offered cosmetic benefit but did not reduce postoperative pain, length of hospitalization, or cost [",
"      <a class=\"abstract\" href=\"UTD.htm?29/38/30310/abstract/9\">",
"       9",
"      </a>",
"      ]. In addition, the complications seen with conventional surgery still occur [",
"      <a class=\"abstract\" href=\"UTD.htm?29/38/30310/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among high-risk elderly patients, minimally invasive aortic valve surgery took longer than conventional surgery and was associated with a higher morbidity and mortality (43 versus 7 percent for conventional surgery) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/38/30310/abstract/11\">",
"       11",
"      </a>",
"      ]. Among elderly patients not otherwise at high risk, morbidity and mortality were not increased [",
"      <a class=\"abstract\" href=\"UTD.htm?29/38/30310/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some have advocated minimally invasive aortic valve surgery using a partial sternotomy for patients who require a second aortic valve replacement or for those who have previously undergone coronary artery bypass graft surgery (CABG). Advantages of this approach include reduction in surgical trauma and blood loss due to avoidance of lower mediastinal surgical dissection and potential injury to cardiac structures, especially patent CABG conduits [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30310/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Large prospective nonrandomized databases have reported equivalent or better results to conventional full sternotomy AVR with equivalent durability in appropriately selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30310/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a full sternotomy approach is commonly recommended for reoperative aortic valve surgery since it provides optimum exposure and control. A non-sternotomy approach significantly limits the ability to perform concomitant surgical revascularization or a maze procedure to prevent recurrent atrial fibrillation and ability to control open surgical grafts in patients with prior revascularization (particularly a patent left internal mammary artery graft).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12099460\">",
"    <span class=\"h2\">",
"     Sutureless aortic valve surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;A new generation of bioprosthetic valves has been developed that mount conventional valves on stented scaffolding and allow a more rapid implantation of valves with minimal or no anchoring sutures [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30310/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. In contrast to transcatheter aortic valve replacement (TAVR or TAVI), this approach entails removal of all pathological leaflet and annular aortic valve calcification, thus facilitating implantation of a larger expandable prosthesis. Since no or minimal (one to three) guiding or anchoring sutures are needed, cross clamp times were dramatically reduced to less than 20 minutes, as were cardiopulmonary bypass times. However, longer-term follow-up on this novel technique is limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mitral valve surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mitral valve can be approached either through a parasternal incision, excising the cartilaginous portions of the third or fourth ribs; a partial sternal split; through a limited right thoracotomy incision (single or smaller multiple incisions for a robotic approach); or through a lower (partial j) hemi-sternotomy. The mitral valve can be visualized either directly through the left atrium or through the right atrium via the interatrial septum. The latter technique requires repair of the iatrogenic atrial septal defect at the conclusion of the procedure. This may be associated with transient atrial conduction abnormalities, which are junctional rhythm that typically resolves in days unless patients have underlying sinus node pathology.",
"   </p>",
"   <p>",
"    Visualization of the mitral valve through these smaller incisions can be further enhanced by thoracoscopic instruments, including more advanced instruments that recreate 3D (depth) stereoscopic visualization. Direct mediastinal cannulation or cannulation of the common femoral vessels is with either a conventional aortic cross clamp or an endoaortic cross clamp (Heartport) techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Possible advantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smaller incisions are associated with the following benefits:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A decrease in postoperative pain",
"     </li>",
"     <li>",
"      Enhanced early sternal stability (more limited sternal precautions and earlier return to full unrestricted activity)",
"     </li>",
"     <li>",
"      More complete and rapid recuperation",
"     </li>",
"     <li>",
"      Decreased risk of sternal infection and instability (in reoperations)",
"     </li>",
"     <li>",
"      Fewer postoperative pulmonary complications",
"     </li>",
"     <li>",
"      Superior cosmetic result",
"     </li>",
"     <li>",
"      Fewer transfusions",
"     </li>",
"     <li>",
"      A shorter length of hospitalization",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Possible disadvantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several potential disadvantages to minimally invasive valvular surgery:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      None of these alternative techniques avoids complications related to aortic manipulation and instrumentation (cannulation, clamping, decannulation) and artificial perfusion with CPB. These account for most of the morbidity related to cardiac surgery.",
"     </li>",
"     <li>",
"      Even in the absence of overt peripheral vascular pathology, retrograde arterial perfusion through the femoral artery may be associated with a small (1 to 2 percent) incidence of vascular complications, including embolization, thrombosis, pseudo-aneurysm, arterial dissection, lymphatic leaks, and groin infections. Peripheral vascular atheromatous disease should be assessed and excluded (via computed tomography or magnetic resonance). Retrograde arterial perfusion may be associated with increased incidence of stroke in higher risk patients [",
"      <a class=\"abstract\" href=\"UTD.htm?29/38/30310/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Visualization of the mitral and aortic valves is adequate but more limited and surgery is more technically demanding. This is of even more critical importance in valve procedures that require three-dimensional spatial orientation and reconstruction, such as a Ross autograft or stentless valve implantation or complex (combined anterior and posterior leaflet) mitral valve chordal repairs or replacement with artificial polytetrafluoroethylene substitutes. In these circumstances, depth perception for neo-chordal length determination and for accurate tying and suturing is needed.",
"     </li>",
"     <li>",
"      Complete evacuation and removal of air trapped in the left ventricle is more difficult and incomplete. This should be monitored with TEE and can be ameliorated with CO2 field insufflation (CO2 is heavier and more soluble than air).",
"     </li>",
"     <li>",
"      Anterior thoracotomy and parasternal incisions may be associated with an increased wound complications rate, including complications such as incisional hernias, dehiscence, seroma formation and infection [",
"      <a class=\"abstract\" href=\"UTD.htm?29/38/30310/abstract/20\">",
"       20",
"      </a>",
"      ]. Prior right thoracotomy and severe pulmonary disease and pulmonary hypertension may preclude safe robotic or port access thoracoscopic approaches since single lung ventilation is required as the patient is weaned from bypass to inspect suture lines.",
"     </li>",
"     <li>",
"      Because of the limited access, the ability to perform concomitant CABG, if required, is technically very difficult. When clinically appropriate, coronary artery disease may be addressed with staged percutaneous coronary intervention. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link\">",
"       \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The full right and left sided surgical maze procedure to prevent recurrent atrial fibrillation and left atrial appendage amputation (to reduce risk of stroke) is more difficult with minimally invasive valve surgery through a limited thoracotomy. As an alternative to the maze procedure, ablation may be accomplished via an endocardial rather than epicardial approach with cryo or uni-polar RF energy sources. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=see_link\">",
"       \"Surgical approaches to prevent recurrent atrial fibrillation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link\">",
"       \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The pericardium and multiple port access incisions are less effectively inspected and drained during surgery, and drainage may be impaired in the postoperative period, resulting in subacute tamponade in the presence of excess post-operative mediastinal drainage.",
"     </li>",
"     <li>",
"      The peripheral cannulation approach using a femoral arterial cannula with an inflatable endo-aortic balloon used to separate cardiac from systemic circulation in place of a cross clamp is significantly more costly than conventional bypass and requires specialized equipment. In addition, appropriate positioning of the endoaortic balloon clamp, the pulmonary artery vent, and the coronary sinus cardioplegia catheters requires technical experience and expertise on the part of the surgeon and anesthesiologist. Fluoroscopy and TEE are required for optimal placement. Alternatively specialized cross clamps need to be used. Placement across the aorta is technically more complex in reoperations because of presence of adhesions and potentially live grafts.",
"     </li>",
"     <li>",
"      Myocardial protection and cardioplegia delivery are of increased importance as cross clamp and pump times tend to be longer, control of live grafts (such as left internal mammary artery graft) is much more challenging, and there is reliance on myocardial cooling and retrograde cardioplegia. Placement of these catheters requires expertise, particularly in robotic surgery. Placement of coronary sinus retrograde cardioplegia requires more expensive specialized percutaneous catheters. Optimal and safe placement requires experience, as well as fluoroscopy and transesophageal echocardiography.",
"     </li>",
"     <li>",
"      All minimally invasive non-sternotomy MV surgical approaches require femoral cannulation. Careful evaluation and exclusion of atheromatous peripheral vascular disease is required.",
"     </li>",
"     <li>",
"      The learning curve for these limited incision procedures may be steeper",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Robotic technologies and improved laparoscopic three-dimensional visualization techniques used in conjunction with specially designed CPB techniques (vacuum assist, smaller cannulas, flexible transthoracic aortic cross clamps, clips, or other techniques to simplify tying) may facilitate accurate repair of complex mitral valve lesions through smaller incisions with comparable results to open techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30310/abstract/21\">",
"     21",
"    </a>",
"    ]. These techniques can also be utilized at the time of mitral valve surgery to treat concomitant atrial fibrillation with either \"cut-and-sew\" or less invasive maze procedure (cryo or radiofrequency ablation) with excellent outcomes and restoration of sinus rhythm in over 80 percent of patients. In addition, amputation of the left atrial appendage can further decrease thromboembolic risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=see_link\">",
"     \"Surgical approaches to prevent recurrent atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21686?source=see_link\">",
"     \"Nonpharmacologic therapy to prevent embolization in patients with atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the cost effectiveness and clinical merit of these advances compared to those of more conventional limited right thoracotomy or partial sternotomy mitral valve surgical approaches remain to be determined.",
"   </p>",
"   <p>",
"    Although the initial results are favorable, there are as yet no randomized comparisons of conventional and alternative approaches to valve surgery with regard to clinical outcomes, postoperative complications, and cost. While the results for isolated minimal access aortic valve surgery have been uniformly encouraging, the results for minimally invasive, port access mitral valve surgery have been more controversial with mixed results in early studies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30310/abstract/22-25\">",
"     22-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As for aortic valve surgery, growing clinical experience and large prospective nonrandomized registries have demonstrated that less invasive surgical approaches to the mitral valve can be performed with very low peri-operative morbidity similar and perhaps lower compared to conventional surgery with equivalent long-term outcomes in appropriately selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30310/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 707 patients undergoing minimally invasive mitral valve repair between 1996 and 2007, operative mortality was 0.4 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?29/38/30310/abstract/26\">",
"       26",
"      </a>",
"      ]. The rate of reoperation for bleeding was 2 percent, stroke occurred in 1.9 percent, deep sternal wound infection occurred in 0.7 percent, and aortic dissection in 0.4 percent. Median hospital stay was five days. During mean follow-up of 5.7 years, there were late deaths in 6.9 percent and failure repairs necessitating reoperation in 4.8 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, comparisons between minimally invasive and open surgery are indirect as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective comparison was performed between early outcomes for 350 patients undergoing thoracoscopic port access mitral valve repair at one institution and those for 365 patients undergoing conventional open repairs at another institution [",
"      <a class=\"abstract\" href=\"UTD.htm?29/38/30310/abstract/28\">",
"       28",
"      </a>",
"      ]. Bypass time (140 versus 33 minutes) and cross clamp times (104 versus 24 minutes) were significantly longer with thoracoscopic port access surgery, but no differences were noted in postoperative blood loss, transfusion, length of hospital stay, or mortality.",
"     </li>",
"     <li>",
"      A review of experience for 1071 patients undergoing minimally invasive mitral valve repair (right anterior minithoracotomy) and 530 patients undergoing sternotomy mitral repair was performed at a single institution between 1986 and 2008 [",
"      <a class=\"abstract\" href=\"UTD.htm?29/38/30310/abstract/27\">",
"       27",
"      </a>",
"      ]. However, the data were not contemporaneous since the minimally invasive approach constituted the bulk of procedures from 1998 to 2008 while the sternotomy approach data began in 1986 and constituted a minority of procedures after 1997. Hospital mortality was the same for patients undergoing minimally invasive and isolated sternotomy mitral valve repairs (1.3 percent for both). Eight-year freedom from reoperation or severe recurrent mitral regurgitation was similar for minimally invasive and sternotomy approaches (93 and 90 percent, respectively).",
"     </li>",
"     <li>",
"      Another review of single center experience with 2124 patient undergoing isolated mitral valve surgery between 1995 and 2004 studied 590 matched pairs (56 percent of total) of patients undergoing minimally invasive or conventional procedures. There were no differences in mortality, stroke, renal failure, myocardial infarction, or infection between conventional and minimally invasive MV surgery. Transfusion rates were modestly lower with the minimally invasive approach (30 versus 37 percent). Early pain scores were better with minimally invasive surgery but were similar in both groups by 48 hours post-operatively. Early pulmonary function (FEV",
"      <sub>",
"       1",
"      </sub>",
"      ) were better with minimally invasive surgery, but were similar in both groups by 72 hours post-operatively [",
"      <a class=\"abstract\" href=\"UTD.htm?29/38/30310/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H456670\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most surgical approaches to valve surgery require cardiopulmonary bypass (CPB) and cardioplegic arrest, ie, open cardiac procedures, although percutaneous aortic and pulmonic valve techniques are available. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Minimally invasive cardiac valvular surgery'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39411?source=see_link\">",
"       \"Percutaneous aortic valvotomy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      New approaches to aortic and mitral valve surgery during cardiopulmonary bypass (CPB) have explored the use of alternative incisions to median sternotomy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Minimally invasive cardiac valvular surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Minimally invasive aortic valve surgery using a partial sternotomy may be a preferred approach for patients who require a second aortic valve replacement or for those who have previously undergone a coronary artery bypass graft surgery (CABG). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Aortic valve surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The results for minimally invasive, port access mitral valve surgery have been mixed. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Mitral valve surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30310/abstract/1\">",
"      Cosgrove DM 3rd, Sabik JF, Navia JL. Minimally invasive valve operations. Ann Thorac Surg 1998; 65:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30310/abstract/2\">",
"      Grossi EA, Galloway AC, Ribakove GH, et al. Impact of minimally invasive valvular heart surgery: a case-control study. Ann Thorac Surg 2001; 71:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30310/abstract/3\">",
"      Cosgrove DM 3rd, Sabik JF. Minimally invasive approach for aortic valve operations. Ann Thorac Surg 1996; 62:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30310/abstract/4\">",
"      Navia JL, Cosgrove DM 3rd. Minimally invasive mitral valve operations. Ann Thorac Surg 1996; 62:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30310/abstract/5\">",
"      Fann JI, Pompili MF, Stevens JH, et al. Port-access cardiac operations with cardioplegic arrest. Ann Thorac Surg 1997; 63:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30310/abstract/6\">",
"      M&auml;chler HE, Bergmann P, Anelli-Monti M, et al. Minimally invasive versus conventional aortic valve operations: a prospective study in 120 patients. Ann Thorac Surg 1999; 67:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30310/abstract/7\">",
"      Sharony R, Grossi EA, Saunders PC, et al. Minimally invasive aortic valve surgery in the elderly: a case-control study. Circulation 2003; 108 Suppl 1:II43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30310/abstract/8\">",
"      Remadi JP, Rakotoarivello Z, Marticho P, et al. Aortic valve replacement with the minimal extracorporeal circulation (Jostra MECC System) versus standard cardiopulmonary bypass: a randomized prospective trial. J Thorac Cardiovasc Surg 2004; 128:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30310/abstract/9\">",
"      Szwerc MF, Benckart DH, Wiechmann RJ, et al. Partial versus full sternotomy for aortic valve replacement. Ann Thorac Surg 1999; 68:2209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30310/abstract/10\">",
"      Kort S, Applebaum RM, Grossi EA, et al. Minimally invasive aortic valve replacement: echocardiographic and clinical results. Am Heart J 2001; 142:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30310/abstract/11\">",
"      Bridgewater B, Steyn RS, Ray S, Hooper T. Minimally invasive aortic valve replacement through a transverse sternotomy: a word of caution. Heart 1998; 79:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30310/abstract/12\">",
"      Byrne JG, Aranki SF, Couper GS, et al. Reoperative aortic valve replacement: partial upper hemisternotomy versus conventional full sternotomy. J Thorac Cardiovasc Surg 1999; 118:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30310/abstract/13\">",
"      Tabata M, Khalpey Z, Shekar PS, Cohn LH. Reoperative minimal access aortic valve surgery: minimal mediastinal dissection and minimal injury risk. J Thorac Cardiovasc Surg 2008; 136:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30310/abstract/14\">",
"      Wu JM, Yao CT, Kan CD, et al. Postoperative chylothorax: differences between patients who received median sternotomy or lateral thoracotomy for congenital heart disease. J Card Surg 2006; 21:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30310/abstract/15\">",
"      Tabata M, Umakanthan R, Cohn LH, et al. Early and late outcomes of 1000 minimally invasive aortic valve operations. Eur J Cardiothorac Surg 2008; 33:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30310/abstract/16\">",
"      Martens S, Sadowski J, Eckstein FS, et al. Clinical experience with the ATS 3f Enable&reg; Sutureless Bioprosthesis. Eur J Cardiothorac Surg 2011; 40:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30310/abstract/17\">",
"      Flameng W, Herregods MC, Hermans H, et al. Effect of sutureless implantation of the Perceval S aortic valve bioprosthesis on intraoperative and early postoperative outcomes. J Thorac Cardiovasc Surg 2011; 142:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30310/abstract/18\">",
"      Santarpino G, Pfeiffer S, Schmidt J, et al. Sutureless aortic valve replacement: first-year single-center experience. Ann Thorac Surg 2012; 94:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30310/abstract/19\">",
"      Grossi EA, Loulmet DF, Schwartz CF, et al. Evolution of operative techniques and perfusion strategies for minimally invasive mitral valve repair. J Thorac Cardiovasc Surg 2012; 143:S68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30310/abstract/20\">",
"      Ng PC, Chua AN, Swanson MS, et al. Anterior thoracotomy wound complications in minimally invasive direct coronary artery bypass. Ann Thorac Surg 2000; 69:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30310/abstract/21\">",
"      Mohr FW, Falk V, Diegeler A, et al. Computer-enhanced \"robotic\" cardiac surgery: experience in 148 patients. J Thorac Cardiovasc Surg 2001; 121:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30310/abstract/22\">",
"      Aklog L, Adams DH, Couper GS, et al. Techniques and results of direct-access minimally invasive mitral valve surgery: a paradigm for the future. J Thorac Cardiovasc Surg 1998; 116:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30310/abstract/23\">",
"      Chitwood WR Jr, Wixon CL, Elbeery JR, et al. Video-assisted minimally invasive mitral valve surgery. J Thorac Cardiovasc Surg 1997; 114:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30310/abstract/24\">",
"      Mohr FW, Falk V, Diegeler A, et al. Minimally invasive port-access mitral valve surgery. J Thorac Cardiovasc Surg 1998; 115:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30310/abstract/25\">",
"      Grossi EA, LaPietra A, Ribakove GH, et al. Minimally invasive versus sternotomy approaches for mitral reconstruction: comparison of intermediate-term results. J Thorac Cardiovasc Surg 2001; 121:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30310/abstract/26\">",
"      McClure RS, Cohn LH, Wiegerinck E, et al. Early and late outcomes in minimally invasive mitral valve repair: an eleven-year experience in 707 patients. J Thorac Cardiovasc Surg 2009; 137:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30310/abstract/27\">",
"      Galloway AC, Schwartz CF, Ribakove GH, et al. A decade of minimally invasive mitral repair: long-term outcomes. Ann Thorac Surg 2009; 88:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30310/abstract/28\">",
"      Suri RM, Schaff HV, Meyer SR, Hargrove WC 3rd. Thoracoscopic versus open mitral valve repair: a propensity score analysis of early outcomes. Ann Thorac Surg 2009; 88:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30310/abstract/29\">",
"      Svensson LG, Atik FA, Cosgrove DM, et al. Minimally invasive versus conventional mitral valve surgery: a propensity-matched comparison. J Thorac Cardiovasc Surg 2010; 139:926.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8128 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-8C269A7C77-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_38_30310=[""].join("\n");
var outline_f29_38_30310=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H456670\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MINIMALLY INVASIVE CARDIAC VALVULAR SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Aortic valve surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12099460\">",
"      Sutureless aortic valve surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mitral valve surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Possible advantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Possible disadvantages",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H456670\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/16/44296?source=related_link\">",
"      Minimally invasive coronary artery bypass graft surgery: Definitions and technical issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21686?source=related_link\">",
"      Nonpharmacologic therapy to prevent embolization in patients with atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37031?source=related_link\">",
"      Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39411?source=related_link\">",
"      Percutaneous aortic valvotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=related_link\">",
"      Radiofrequency catheter ablation to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=related_link\">",
"      Surgical approaches to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/29/34264?source=related_link\">",
"      Transcatheter aortic valve replacement",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_38_30311="Aminocaproic acid: Drug information";
var content_f29_38_30311=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aminocaproic acid: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/17/30996?source=see_link\">",
"    see \"Aminocaproic acid: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/32/14854?source=see_link\">",
"    see \"Aminocaproic acid: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F133225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Amicar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F133261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antifibrinolytic Agent;",
"     </li>",
"     <li>",
"      Antihemophilic Agent;",
"     </li>",
"     <li>",
"      Hemostatic Agent;",
"     </li>",
"     <li>",
"      Lysine Analog",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F133228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute bleeding:",
"     </b>",
"     Oral, I.V.: Loading dose: 4-5 g during the first hour, followed by 1 g/hour for 8 hours (or 1.25 g/hour using oral solution) or until bleeding controlled (maximum daily dose: 30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Control of bleeding with severe thrombocytopenia (unlabeled use) (Bartholomew, 1989; Gardner, 1980):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial: I.V.: 100 mg/kg (maximum dose: 5 g) over 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance: Oral, I.V.: 1-4 g every 4-8 hours or 1 g/hour (maximum daily dose: 24 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Control of oral bleeding in congenital and acquired coagulation disorder (unlabeled use):",
"     </b>",
"     Oral: 50-60 mg/kg every 4 hours (Mannucci, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of dental procedure bleeding in patients on oral anticoagulant therapy (unlabeled use):",
"     </b>",
"     Oral rinse: Hold 4 g/10 mL in mouth for 2 minutes then spit out. Repeat every 6 hours for 2 days after procedure (Souto, 1996). Concentration and frequency may vary by institution and product availability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of perioperative bleeding associated with cardiac surgery (unlabeled use):",
"     </b>",
"     I.V.: Loading dose of 75-150 mg/kg (typically 5-10 g), followed by 10-15 mg/kg/hour (typically 1 g/hour); may add 2-2.5 g/L of cardiopulmonary bypass circuit priming solution (Gravlee, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loading dose of 10 g followed by 2 g/hour during surgery; no medication added to the bypass circuit (Fergusson, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 g over 20-30 minutes prior to skin incision, followed by 10 g after heparin administration then 10 g at discontinuation of cardiopulmonary bypass (Vander Salm, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Traumatic hyphema (unlabeled use):",
"     </b>",
"     Oral: 50 mg/kg/dose every 4 hours (maximum daily dose: 30 g) for 5 days (Brandt, 2001; Crouch, 1999)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F133246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/32/14854?source=see_link\">",
"      see \"Aminocaproic acid: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of perioperative bleeding associated with cardiac surgery (unlabeled use):",
"     </b>",
"     I.V.: 100 mg/kg given over 20-30 minutes after induction and prior to incision, 100 mg/kg during cardiopulmonary bypass, and 100 mg/kg after heparin reversal over 3 hours (Chauhan, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of bleeding associated with extracorporeal membrane oxygenation (ECMO) (unlabeled use):",
"     </b>",
"     I.V.: 100 mg/kg prior to or immediately after cannulation, followed by 25-30 mg/kg/hour for up to 72 hours (Downard, 2003; Horwitz, 1998; Wilson, 1993)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of perioperative bleeding associated with spinal surgery (eg, idiopathic scoliosis) (unlabeled use):",
"     </b>",
"     Children and Adolescents: I.V.: 100 mg/kg given over 15-20 minutes after induction, followed by 10 mg/kg/hour for the remainder of the surgery; discontinue at time of wound closure (Florentino-Pineda, 2001; Florentino-Pineda, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Traumatic hyphema (unlabeled use):",
"     </b>",
"     Oral: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F133229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F133230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May accumulate in patients with decreased renal function. When used during cardiopulmonary bypass in anephric patients, a normal or slightly reduced loading dose and a continuous infusion rate of 5 mg/kg/hour has been recommended (Gravlee, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15671610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F133202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 250 mg/mL (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 1.25 g/5 mL (237 mL, 473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amicar&reg;: 1.25 g/5 mL (473 mL) [raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amicar&reg;: 500 mg, 1000 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F133186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F133205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rapid I.V. injection (IVP) of undiluted solution is not recommended due to possible hypotension, bradycardia, and arrhythmia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: May administer loading dose over 15-60 minutes depending on indication; a continuous infusion may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14471315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     5000 mg in 250 mL (concentration: 20 mg/mL) of D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, or Ringer&rsquo;s injection",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F133268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, Ringer&rsquo;s injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible",
"     </b>",
"     with fenoldopam",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F133204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To enhance hemostasis when fibrinolysis contributes to bleeding (causes may include cardiac surgery, hematologic disorders, neoplastic disorders, abruptio placentae, hepatic cirrhosis, and urinary fibrinolysis)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F133258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of traumatic hyphema; control bleeding in thrombocytopenia; control oral bleeding in congenital and acquired coagulation disorders; topical treatment (mouth rinse) of bleeding associated with dental procedures in patients on oral anticoagulant therapy; prevention of perioperative bleeding associated with cardiac surgery; prevention of bleeding associated with extracorporeal membrane oxygenation (ECMO); prevention of perioperative bleeding associated with spinal surgery (eg, idiopathic scoliosis)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F133270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Amicar&reg; may be confused with amikacin, Amikin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Amicar [U.S.] may be confused with Omacor brand name for Omega-3-Acid Ethyl Esters [multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F133259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, bradycardia, edema, hypotension, intracranial hypertension, peripheral ischemia, syncope, thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion, delirium, dizziness, fatigue, hallucinations, headache, malaise, seizure, stroke",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash, pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, cramps, diarrhea, GI irritation, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dry ejaculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, bleeding time increased, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site necrosis, injection site pain, injection site reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: CPK increased, myalgia, myositis, myopathy, rhabdomyolysis (rare), weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ophthalmic: Vision decreased, watery eyes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased, intrarenal obstruction (glomerular capillary thrombosis), myoglobinuria (rare), renal failure (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, nasal congestion, pulmonary embolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, anaphylactoid reaction, anaphylaxis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Hepatic lesion, hyperkalemia, myocardial lesion",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F133208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Disseminated intravascular coagulation (without heparin); evidence of an active intravascular clotting process",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F133190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intrarenal obstruction: May occur secondary to glomerular capillary thrombosis or clots in the renal pelvis and ureters; do not use in hematuria of upper urinary tract origin unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skeletal muscle weakness: Ranging from mild myalgias and fatigue to severe myopathy with rhabdomyolysis and acute renal failure has been reported with prolonged use. Monitor CPK; discontinue treatment with a rise in CPK.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; may accumulate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood products: Do not administer with factor IX complex concentrates or anti-inhibitor coagulant complexes; may increase risk for thrombosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Injection contains benzyl alcohol which has been associated with \"gasping syndrome\" in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Do not administer without a definite diagnosis of laboratory findings indicative of hyperfibrinolysis. Inhibition of fibrinolysis may promote clotting or thrombosis; more likely due to the presence of DIC.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; I.V. administration: Avoid rapid I.V. administration; may induce hypotension, bradycardia, or arrhythmia; rapid injection of undiluted solution is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F133195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-inhibitor Coagulant Complex: Antifibrinolytic Agents may enhance the thrombogenic effect of Anti-inhibitor Coagulant Complex.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Factor IX (Human): Aminocaproic Acid may enhance the adverse/toxic effect of Factor IX (Human). Specifically, use of this combination may increase the risk of thrombosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Factor IX (Recombinant): Aminocaproic Acid may enhance the adverse/toxic effect of Factor IX (Recombinant). Specifically, use of this combination may increase the risk of thrombosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Factor IX Complex (Human): Aminocaproic Acid may enhance the adverse/toxic effect of Factor IX Complex (Human). Specifically, use of this combination may increase the risk of thrombosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibrinogen Concentrate (Human): Antifibrinolytic Agents may enhance the adverse/toxic effect of Fibrinogen Concentrate (Human). Specifically, the risk for thrombosis may be increased. Fibrinogen Concentrate (Human) may enhance the adverse/toxic effect of Antifibrinolytic Agents. Specifically, the risk for thrombosis may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tretinoin (Systemic): May enhance the thrombogenic effect of Antifibrinolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F133198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F133211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F133236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F133210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Aminocaproic Acid Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg/mL (20 mL): $1.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Amicar Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25% (473 mL): $794.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Aminocaproic Acid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25% (237 mL): $365.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Amicar Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $333.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mg (100): $752.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Aminocaproic Acid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $312.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mg (100): $897.32",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F133200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fibrinogen, fibrin split products, creatine phosphokinase (with long-term therapy), BUN, creatinine",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acepramin (HN, HU);",
"     </li>",
"     <li>",
"      Acidum e-aminocapronicum (PL);",
"     </li>",
"     <li>",
"      Amicar (AE, AU, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE, ZA);",
"     </li>",
"     <li>",
"      Caproamin (ES, VE);",
"     </li>",
"     <li>",
"      Caproamin Fides (ES);",
"     </li>",
"     <li>",
"      Caprolest (NL);",
"     </li>",
"     <li>",
"      Caprolisin (IT);",
"     </li>",
"     <li>",
"      EAC (DE);",
"     </li>",
"     <li>",
"      Epsamon (CH);",
"     </li>",
"     <li>",
"      Epsicaprom (PT);",
"     </li>",
"     <li>",
"      Epsilon (FI);",
"     </li>",
"     <li>",
"      Hamostat (IN);",
"     </li>",
"     <li>",
"      Hemocaprol (ES);",
"     </li>",
"     <li>",
"      Hexalense (FR);",
"     </li>",
"     <li>",
"      Ipron (TW);",
"     </li>",
"     <li>",
"      Ipsilon (AR, BR, JP, PY, UY);",
"     </li>",
"     <li>",
"      Kai Nai Yin (CL);",
"     </li>",
"     <li>",
"      Resplamin (JP);",
"     </li>",
"     <li>",
"      Syrop acidi e-aminocapronici (PL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F133189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds competitively to plasminogen; blocking the binding of plasminogen to fibrin and the subsequent conversion to plasmin, resulting in inhibition of fibrin degradation (fibrinolysis).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F133207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: ~1-72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely through intravascular and extravascular compartments",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : Oral: 23 L, I.V.: 30 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Minimally hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Oral: Within 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (65% as unchanged drug, 11% as metabolite)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Banerjee A, Stoica C, and Walia A, \"Acute Hyperkalemia as a Complication of Intravenous Therapy With Epsilon-Aminocaproic Acid,\"",
"      <i>",
"       J Clin Anesth",
"      </i>",
"      , 2011, 23(7):565-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/22050802/pubmed\" id=\"22050802\" target=\"_blank\">",
"        22050802",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartholomew JR, Salgia R, and Bell WR, &ldquo;Control of Bleeding in Patients With Immune and Nonimmune Thrombocytopenia With Aminocaproic Acid,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1989, 149(9):1959-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/2774776/pubmed\" id=\"2774776\" target=\"_blank\">",
"        2774776",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brandt MT and Haug RH, \"Traumatic Hyphema: A Comprehensive Review,\"",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2001, 59(12):1462-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/11732035/pubmed\" id=\"11732035\" target=\"_blank\">",
"        11732035",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Casati V, Guzzon D, Oppizzi M, et al, &ldquo;Hemostatic Effects of Aprotinin, Tranexamic Acid and Epsilon-Aminocaproic Acid in Primary Cardiac Surgery,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 1999, 68(6):2252-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/10617012/pubmed\" id=\"10617012\" target=\"_blank\">",
"        10617012",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chauhan S, Das SN, Bisoi A, et al, &ldquo;Comparison of Epsilon Aminocaproic Acid and Tranexamic Acid in Pediatric Cardiac Surgery,&rdquo;",
"      <i>",
"       J Cardiothorac Vasc Anesth",
"      </i>",
"      , 2004, 18(2):141-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/15073700/pubmed\" id=\"15073700\" target=\"_blank\">",
"        15073700",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Crouch ER Jr and Crouch ER, \"Management of Traumatic Hyphema: Therapeutic Options,\"",
"      <i>",
"       J Pediatr Ophthalmol Strabismus",
"      </i>",
"      , 1999, 36(5):238-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/10505828/pubmed\" id=\"10505828\" target=\"_blank\">",
"        10505828",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Crouch ER Jr, Williams PB, Gray MK, et al, &ldquo;Topical Aminocaproic Acid in the Treatment of Traumatic Hyphema,&rdquo;",
"      <i>",
"       Arch Ophthalmol",
"      </i>",
"      , 1997, 115(9):1106-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/9298049/pubmed\" id=\"9298049\" target=\"_blank\">",
"        9298049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Daily PO, Lamphere JA, Dembitsky WP, et al, &ldquo;Effect of Prophylactic Epsilon-Aminocaproic Acid on Blood Loss and Transfusion Requirements in Patients Undergoing First-time Coronary Artery Bypass Grafting: A Randomized, Pprospective, Double-Blind Study,&rdquo;",
"      <i>",
"       J Thorac Cardiovasc Surg",
"      </i>",
"      , 1994, 108(1):99-108.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/8028387/pubmed\" id=\"8028387\" target=\"_blank\">",
"        8028387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Peppo A, Pierri MD, Scafuri A, et al, &ldquo;Intraoperative Antifibrinolysis and Blood-Saving Techniques in Cardiac Surgery: Prospective Trial of 3 Antifibrinolytic Drugs,&rdquo;",
"      <i>",
"       Tex Heart Inst J",
"      </i>",
"      , 1995, 22(3):231-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/7580360/pubmed\" id=\"7580360\" target=\"_blank\">",
"        7580360",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Downard CD, Betit P, Chang RW, et al, \"Impact of AMICAR on Hemorrhagic Complications of ECMO: A Ten-Year Review,\"",
"      <i>",
"       J Pediatr Surg",
"      </i>",
"      , 2003, 38(8):1212-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/12891495/pubmed\" id=\"12891495\" target=\"_blank\">",
"        12891495",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eaton MP, &ldquo;Antifibrinolytic Therapy in Surgery for Congenital Heart Disease,&rdquo;",
"      <i>",
"       Anest Analg",
"      </i>",
"      , 2008, 106(4):1087-100.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/18349177/pubmed\" id=\"18349177\" target=\"_blank\">",
"        18349177",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eberle B, Mayer E, Hafner G, et al, &ldquo;High-Dose Epsilon-Aminocaproic Acid Versus Aprotinin: Antifibrinolytic Efficacy in First-Time Coronary Operations,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 1998, 65(3):667-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/9527193/pubmed\" id=\"9527193\" target=\"_blank\">",
"        9527193",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fergusson DA, Hebert PC, Mazer CD, et al, &ldquo;A Comparison of Aprotinin and Lysine Analogues in High-Risk Cardiac Surgery,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(22):2319-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/18480196/pubmed\" id=\"18480196\" target=\"_blank\">",
"        18480196",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Florentino-Pineda I, Blakemore LC, Thompson GH, et al, \"The Effect of Epsilon-Aminocaproic Acid on Perioperative Blood Loss in Patients With Idiopathic Scoliosis Undergoing Posterior Spinal Fusion: A Preliminary Prospective Study,\"",
"      <i>",
"       Spine (Phila Pa 1976)",
"      </i>",
"      , 2001, 26(10):1147-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/11413428/pubmed\" id=\"11413428\" target=\"_blank\">",
"        11413428",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Florentino-Pineda I, Thompson GH, Poe-Kochert C, et al, \"The Effect of Amicar on Perioperative Blood Loss in Idiopathic Scoliosis: The Results of a Prospective, Randomized Double-Blind Study,\"",
"      <i>",
"       Spine (Phila Pa 1976)",
"      </i>",
"      , 2004, 29(3):233-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/14752343/pubmed\" id=\"14752343\" target=\"_blank\">",
"        14752343",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gardner FH and Helmer RE 3rd, &ldquo;Aminocaproic Acid. Use in Control of Hemorrhage in Patients With Amegakaryocytic Thrombocytopenia,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1980, 243(1):35-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/6965311/pubmed\" id=\"6965311\" target=\"_blank\">",
"        6965311",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gravlee GP and Spiess B, \"Pharmacologic Prophylaxis for Post-Cardiopulmonary Bypass Bleeding,\"",
"      <i>",
"       Cardiopulmonary Bypass: Principles and Practice",
"      </i>",
"      , 3rd ed, Philadelphia, PA: Lippincott Williams &amp; Wilkins, 2008, 522-42.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):7-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/22315257/pubmed\" id=\"22315257\" target=\"_blank\">",
"        22315257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Haut MT, Mauro VF, and Davis HH, &ldquo;Effect of Renal Failure and Hemodialysis on Aminocaproic Acid Plasma Concentrations,&rdquo;",
"      <i>",
"       DICP",
"      </i>",
"      , 1989, 23(11):922-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/2596137/pubmed\" id=\"2596137\" target=\"_blank\">",
"        2596137",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Horwitz JR, Cofer BR, Warner BW, et al, \"A Multicenter Trial of 6-Aminocaproic Acid (Amicar) in the Prevention of Bleeding in Infants on ECMO,\"",
"      <i>",
"       J Pediatr Surg",
"      </i>",
"      , 1998, 33(11):1610-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/9856877/pubmed\" id=\"9856877\" target=\"_blank\">",
"        9856877",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kikura M, Levy JH, Tanaka KA, et al, &ldquo;A Double-Blind, Placebo-Controlled Trial of Epsilon-Aminocaproic Acid for Reducing Blood Loss in Coronary Artery Bypass Grafting Surgery,&rdquo;",
"      <i>",
"       J Am Coll Surg",
"      </i>",
"      , 2006, 202(2):216-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/16427545/pubmed\" id=\"16427545\" target=\"_blank\">",
"        16427545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lucas ON and Albert TW, &ldquo;Epsilon Aminocaproic Acid in Hemophiliacs Undergoing Dental Extractions: A Concise Review,&rdquo;",
"      <i>",
"       Oral Surg Oral Med Oral Pathol",
"      </i>",
"      , 1981, 51(2):115-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/6782532/pubmed\" id=\"6782532\" target=\"_blank\">",
"        6782532",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mannucci P, &ldquo;Hemostatic Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 339(4):245-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/9673304/pubmed\" id=\"9673304\" target=\"_blank\">",
"        9673304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McGetrick JJ, Jampol LM, Goldberg MP, et al, &ldquo;Aminocaproic Acid Decreases Secondary Hemorrhage After Traumatic Hyphema,&rdquo;",
"      <i>",
"       Arch Ophthalmol",
"      </i>",
"      , 1983, 101(7):1031-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/6870623/pubmed\" id=\"6870623\" target=\"_blank\">",
"        6870623",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nzerue CM and Falana B, \"Refractory Hyperkalaemia Associated With Use of Epsilon-Aminocaproic Acid During Coronary Bypass in a Dialysis Patient,\"",
"      <i>",
"       Nephrol Dial Transplant",
"      </i>",
"      , 2002, 17(6):1150-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/12032221/pubmed\" id=\"12032221\" target=\"_blank\">",
"        12032221",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Patatanian E and Fugate SE,, &ldquo;Hemostatic Mouthwashes in Anticoagulated Patients Undergoing Dental Extraction,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2006, 40(12):2205-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/17090725/pubmed\" id=\"17090725\" target=\"_blank\">",
"        17090725",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pieramici DJ, Goldberg MF, Melia M, et al, &ldquo;A Phase III, Multicenter, Randomized, Placebo-Controlled Clinical Trial of Topical Aminocaproic Acid (Caprogel) in the Management of Traumatic Hyphema,&rdquo;",
"      <i>",
"       Ophthalmology",
"      </i>",
"      , 2003, 110(11):2106-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/14597516/pubmed\" id=\"14597516\" target=\"_blank\">",
"        14597516",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pinosky ML, Kennedy DJ, Fishman RL, et al, &ldquo;Tranexamic Acid Reduces Bleeding After Cardiopulmonary Bypass When Compared to Epsilon Aminocaproic Acid and Placebo,&rdquo;",
"      <i>",
"       J Card Surg",
"      </i>",
"      , 1997, 12(5):330-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/9635271/pubmed\" id=\"9635271\" target=\"_blank\">",
"        9635271",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sane DC, Califf RM, Topol EJ, et al, \" Bleeding During Thrombolytic Therapy for Acute Myocardial Infarction: Mechanisms and Management,\"",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1989, 111(12):1010-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/2688504/pubmed\" id=\"2688504\" target=\"_blank\">",
"        2688504",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Souto JC, Olover A, Zuazu-Jausoro I, et al, &ldquo;Oral Surgery in Anticoagulated Patients Without Reducing the Dose of Oral Anticoagulant: A Prospective Randomized Study,&rdquo;",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 1996, 54(1):27-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/8530996/pubmed\" id=\"8530996\" target=\"_blank\">",
"        8530996",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Teboul BK, Jacob JL, Barsoum-Homsy M, et al, &ldquo;Clinical Evaluation of Aminocaproic Acid for Managing Traumatic Hyphema in Children,&rdquo;",
"      <i>",
"       Ophthalmology",
"      </i>",
"      , 1995, 102(11):1646-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/9098257/pubmed\" id=\"9098257\" target=\"_blank\">",
"        9098257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vander Salm TJ, Kaur S, Lancey RA, et al, &ldquo;Reduction of Bleeding After Heart Operations Through the Prophylactic Use of Epsilon-Aminocaproic Acid,&rdquo;",
"      <i>",
"       J Thorac Cardiovasc Surg",
"      </i>",
"      , 1996, 112(4):1098-107",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/8873738/pubmed\" id=\"8873738\" target=\"_blank\">",
"        8873738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walton W, Von Hagen S, Grigorian R, et al, &ldquo;Management of Traumatic Hyphema,&rdquo;",
"      <i>",
"       Surv Ophthalmol",
"      </i>",
"      , 2002, 47(4):297-334.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/12161209/pubmed\" id=\"12161209\" target=\"_blank\">",
"        12161209",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson JM, Bower LK, Fackler JC, et al, \"Aminocaproic Acid Decreases the Incidence of Intracranial Hemorrhage and Other Hemorrhagic Complications of ECMO,\"",
"      <i>",
"       J Pediatr Surg",
"      </i>",
"      , 1993, 28(4):536-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30311/abstract-text/8483066/pubmed\" id=\"8483066\" target=\"_blank\">",
"        8483066",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zhang YP and Trissel LA, &ldquo;Stability of Aminocaproic Acid Injection Admixtures in 5% Dextrose Injection and 0.9% Sodium Chloride Injection,&rdquo;",
"      <i>",
"       Int J Pharm Compound",
"      </i>",
"      , 1997, 1(2):132-4.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8561 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-6DAE62D42F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_38_30311=[""].join("\n");
var outline_f29_38_30311=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133225\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133261\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133228\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133246\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133229\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133230\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671610\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133202\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133186\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133205\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471315\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133268\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133204\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133258\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133270\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133259\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133208\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133190\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298735\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133195\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133198\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133211\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133236\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133210\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133200\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038523\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133189\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133207\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8561\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8561|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/17/30996?source=related_link\">",
"      Aminocaproic acid: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/32/14854?source=related_link\">",
"      Aminocaproic acid: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_38_30312="Chlorpromazine: Drug information";
var content_f29_38_30312=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chlorpromazine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/11/20661?source=see_link\">",
"    see \"Chlorpromazine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/35/21047?source=see_link\">",
"    see \"Chlorpromazine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F7290573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F150514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Chlorpromazine Hydrochloride Inj;",
"     </li>",
"     <li>",
"      Teva-Chlorpromazine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F150560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antimanic Agent;",
"     </li>",
"     <li>",
"      Antipsychotic Agent, Typical, Phenothiazine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F150518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Schizophrenia/psychoses:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     Range: 30-800 mg/day in 1-4 divided doses, initiate at lower doses and titrate as needed; usual dose: 200-600 mg/day; some patients may require 1-2 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M., I.V.:",
"     </i>",
"     Initial: 25 mg, may repeat (25-50 mg) in 1-4 hours, gradually increase to a maximum of 400 mg/dose every 4-6 hours until patient is controlled; usual dose: 300-800 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intractable hiccups:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral, I.M.:",
"     </i>",
"     25-50 mg 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V. (refractory to oral or I.M. treatment):",
"     </i>",
"     25-50 mg via slow I.V. infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nausea and vomiting:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     10-25 mg every 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M., I.V.:",
"     </i>",
"     25-50 mg every 4-6 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F150539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/35/21047?source=see_link\">",
"      see \"Chlorpromazine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Schizophrenia/psychoses:",
"     </b>",
"     Children &ge;6 months:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     0.5-1 mg/kg/dose every 4-6 hours; older children may require 200 mg/day or higher.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M., I.V.:",
"     </i>",
"     0.5-1 mg/kg/dose every 6-8 hours; maximum dose for &lt;5 years (&lt;22.7 kg): 40 mg/day; maximum for 5-12 years (22.7-45.5 kg): 75 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nausea and vomiting:",
"     </b>",
"     Children &ge;6 months:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     0.5-1 mg/kg/dose every 4-6 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M., I.V.:",
"     </i>",
"     0.5-1 mg/kg/dose every 6-8 hours; maximum dose for &lt;5 years (&lt;22.7 kg): 40 mg/day; maximum for 5-12 years (22.7-45.5 kg): 75 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F150519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Behavioral symptoms associated with dementia (unlabeled use): Initial: 10-25 mg 1-2 times/day; increase at 4- to 7-day intervals by 10-25 mg/day. Increase dose intervals (eg, twice daily, 3 times/day) as necessary to control behavior response or side effects; maximum daily dose: 800 mg; gradual increases (titration) may prevent some side effects or decrease their severity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Other indications: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F150520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not dialyzable (0% to 5%)",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F150521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid use in severe hepatic dysfunction.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F150486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 25 mg/mL (1 mL, 2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 10 mg, 25 mg, 50 mg, 100 mg, 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F150470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F150491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not administer SubQ (tissue damage and irritation may occur); for direct I.V. injection, administer diluted solution slow I.V. at a rate not to exceed 0.5 mg/minute in children and 1 mg/minute in adults. To reduce the risk of hypotension, patients receiving I.V. chlorpromazine must remain lying down during and for 30 minutes after the injection.",
"     <b>",
"      Note:",
"     </b>",
"     Avoid skin contact with solution; may cause contact dermatitis.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F150566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in dextrose, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amsacrine, cisatracurium, cisplatin, cladribine, cyclophosphamide, cytarabine, dexmedetomidine, docetaxel, doxorubicin, doxorubicin liposome, famotidine, fenoldopam, filgrastim, fluconazole, gemcitabine, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, ondansetron, oxaliplatin, potassium chloride, propofol, teniposide, thiotepa, vinorelbine, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, amifostine, amphotericin B cholesteryl sulfate complex, aztreonam, bivalirudin, cefepime, etoposide phosphate, fludarabine, furosemide, linezolid, melphalan, methotrexate, paclitaxel, pantoprazole, pemetrexed, piperacillin/tazobactam, sargramostim, tigecycline.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Remifentanil",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Atropine, benztropine, buprenorphine, butorphanol, diphenhydramine, doxapram, droperidol, fentanyl, glycopyrrolate, hydromorphone, meperidine, metoclopramide, midazolam, pentazocine, prochlorperazine edisylate, promethazine, scopolamine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Cimetidine, pantoprazole, pentobarbital, thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Dimenhydrinate, heparin, hydroxyzine, morphine, ranitidine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F150490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of psychotic disorders (control of mania, treatment of schizophrenia); control of nausea and vomiting; relief of restlessness and apprehension before surgery; acute intermittent porphyria; adjunct in the treatment of tetanus; intractable hiccups; combativeness and/or explosive hyperexcitable behavior in children 1-12 years of age and in short-term treatment of hyperactive children",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F150557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Behavioral symptoms associated with dementia (elderly); psychosis/agitation related to Alzheimer's dementia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F150568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ChlorproMAZINE may be confused with chlordiazePOXIDE, chlorproPAMIDE, clomiPRAMINE, prochlorperazine, promethazine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Thorazine may be confused with thiamine, thioridazine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F150558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Orthostatic hypotension, tachycardia, dizziness, nonspecific QT changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Drowsiness, dystonias, akathisia, pseudoparkinsonism, tardive dyskinesia, neuroleptic malignant syndrome, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Photosensitivity, dermatitis, skin pigmentation (slate gray)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Lactation, breast engorgement, false-positive pregnancy test, amenorrhea, gynecomastia, hyper- or hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia, constipation, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary retention, ejaculatory disorder, impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, eosinophilia, leukopenia, hemolytic anemia, aplastic anemia, thrombocytopenic purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, corneal and lenticular changes, epithelial keratopathy, pigmentary retinopathy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F150494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to chlorpromazine or any component of the formulation (cross-reactivity between phenothiazines may occur); severe CNS depression; coma",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F150474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: May alter cardiac conduction (life-threatening arrhythmias have occurred with therapeutic doses of phenothiazines). May cause QT prolongation and subsequent torsade de pointes; avoid use in patients with diagnosed or suspected congenital long QT syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems. Relative to other neuroleptics, chlorpromazine has a moderate potency of cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, pre-existing low WBC or history of drug-induced leuko/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; use with caution in patients at risk of pneumonia (ie, Alzheimer's disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extrapyramidal symptoms (EPS): May cause extrapyramidal symptoms, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia. Risk of dystonia (and possibly other EPS) may be greater with increased doses, use of conventional antipsychotics, males, and younger patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperprolactinemia: Use associated with increased prolactin levels; clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Significant hypotension may occur, particularly with parenteral administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic malignant syndrome (NMS): May be associated with NMS; monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: May cause pigmentary retinopathy, and lenticular and corneal deposits, particularly with prolonged therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: Highly sedating which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with severe cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo.",
"     </b>",
"     Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Chlorpromazine is not approved for the treatment of dementia-related psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with narrow-angle glaucoma; condition may be exacerbated by cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; condition may be exacerbated by cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Use with caution in patients with Parkinson's disease; they may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory disease (eg, severe asthma, emphysema) due to potential for CNS effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antiemetic effects: May mask toxicity of other drugs or conditions (eg, intestinal obstruction, Reye's syndrome, brain tumor) due to antiemetic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drugs with QT prolongation potential: Avoid concurrent use with other drugs known to prolong QT",
"     <sub>",
"      c",
"     </sub>",
"     interval.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use in patients with dementia is associated with an increased risk of mortality and cerebrovascular accidents; avoid antipsychotic use for behavioral problems associated with dementia unless alternative nonpharmacologic therapies have failed and patient may harm self or others. In addition, may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults. May be inappropriate in older adults depending on comorbidities (eg, delirium) due to its potent anticholinergic effects (Beers Criteria). Increased risk for developing tardive dyskinesia, particularly in elderly women.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfites: Injection contains sulfites.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F150555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2D6 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (moderate), CYP2E1 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F150479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Antipsychotic Agents (Phenothiazines) may enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). Specifically, this may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. Antidepressants (Serotonin Reuptake Inhibitor/Antagonist) may enhance the hypotensive effect of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antimalarial Agents: May increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): May diminish the therapeutic effect of Antipsychotics (Typical). Antipsychotics (Typical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist). Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson's agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Antipsychotic Agents (Phenothiazines) may enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: ChlorproMAZINE may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: ChlorproMAZINE may increase the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: ChlorproMAZINE may enhance the QTc-prolonging effect of Haloperidol. ChlorproMAZINE may increase the serum concentration of Haloperidol. Haloperidol may increase the serum concentration of ChlorproMAZINE.  Management: Consider alternatives to combined treatment with these agents. If combined treatment cannot be avoided, monitor for signs and symptoms of prolonged QTc interval (e.g. arrhythmias).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: ChlorproMAZINE may increase the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F150509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid St John's wort (may decrease chlorpromazine levels, increase photosensitization, or enhance sedative effect). Avoid dong quai (may enhance photosensitization). Avoid kava kava, gotu kola, valerian (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10923687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Embryotoxicity was observed in animal reproduction studies. Jaundice or hyper-/hyporeflexia have been reported in newborn infants following maternal use of phenothiazines. Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F150527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;of concern&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F150496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chlorpromazine and its metabolites have been detected in breast milk; concentrations in the milk do not correlate with those in the  mother and may be higher than what is in the maternal plasma.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (ChlorproMAZINE HCl Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg/mL (1 mL): $19.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (ChlorproMAZINE HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $88.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $145.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $206.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $315.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $391.66",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F150484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs (especially with parenteral use); lipid profile, fasting blood glucose/Hgb A",
"     <sub>",
"      1c",
"     </sub>",
"     ; BMI; mental status; abnormal involuntary movement scale (AIMS); extrapyramidal symptoms (EPS); CBC in patients with risk factors for leukopenia/neutropenia",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F150487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic: 50-300 ng/mL (SI: 157-942 nmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Toxic: &gt;750 ng/mL (SI: &gt;2355 nmol/L); serum concentrations poorly correlate with expected response",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F150497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aminazin (RU);",
"     </li>",
"     <li>",
"      Ampliactil (AR);",
"     </li>",
"     <li>",
"      Aspersinal (AR);",
"     </li>",
"     <li>",
"      Bellacina (PY);",
"     </li>",
"     <li>",
"      Cepezet (ID);",
"     </li>",
"     <li>",
"      Chlorazin (BG, CH);",
"     </li>",
"     <li>",
"      Chlorpromed (TH);",
"     </li>",
"     <li>",
"      Clonazine (IE);",
"     </li>",
"     <li>",
"      Clorpromaz (BR);",
"     </li>",
"     <li>",
"      Clozine (IN);",
"     </li>",
"     <li>",
"      Coliman (TW);",
"     </li>",
"     <li>",
"      Esmind (JP);",
"     </li>",
"     <li>",
"      Fenactil (PL);",
"     </li>",
"     <li>",
"      Globazine (PH);",
"     </li>",
"     <li>",
"      Hibernal (HU, SE);",
"     </li>",
"     <li>",
"      Klorproman (FI);",
"     </li>",
"     <li>",
"      Laractyl (PH);",
"     </li>",
"     <li>",
"      Largactil (AE, AT, AU, BB, BE, BF, BH, BJ, BM, BS, BZ, CI, CN, CR, CY, DO, EG, ES, ET, FR, GB, GH, GM, GN, GR, GT, GY, HN, IE, IQ, IR, IT, JM, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, NE, NG, NI, NL, NO, NZ, OM, PA, PK, PR, PT, QA, SA, SC, SD, SL, SN, SR, SV, SY, TN, TR, TT, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Largo (SG);",
"     </li>",
"     <li>",
"      Matcine (MY, SG, TH);",
"     </li>",
"     <li>",
"      Megatil (IN);",
"     </li>",
"     <li>",
"      Meprosetil (ID);",
"     </li>",
"     <li>",
"      Morefine (TW);",
"     </li>",
"     <li>",
"      Neomazine (KP);",
"     </li>",
"     <li>",
"      Plegomazin (BB, BM, BS, BZ, CZ, GY, IQ, JM, PR, SR, SY, TT);",
"     </li>",
"     <li>",
"      Plegomazine (HU);",
"     </li>",
"     <li>",
"      Pogetol (TH);",
"     </li>",
"     <li>",
"      Promactil (ES, PE);",
"     </li>",
"     <li>",
"      Promazine (PH);",
"     </li>",
"     <li>",
"      Promexin (JP);",
"     </li>",
"     <li>",
"      Propaphenin (DE);",
"     </li>",
"     <li>",
"      Prozil (DK);",
"     </li>",
"     <li>",
"      Prozin (IT);",
"     </li>",
"     <li>",
"      Psynor (PH);",
"     </li>",
"     <li>",
"      Taroctyl (IL);",
"     </li>",
"     <li>",
"      Thorazine (PH);",
"     </li>",
"     <li>",
"      Winsumin (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F150473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chlorpromazine is an aliphatic phenothiazine antipsychotic which blocks postsynaptic mesolimbic dopaminergic receptors in the brain; exhibits a strong alpha-adrenergic blocking effect and depresses the release of hypothalamic and hypophyseal hormones; believed to depress the reticular activating system, thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F150493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.M.: 15 minutes; Oral: 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 20 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 92% to 97%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic to active and inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, biphasic: Initial: 2 hours; Terminal: 30 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;1% as unchanged drug) within 24 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, &ldquo;Reappraisal of Lytic Cocktail/Demerol&reg;, Phenergan&reg;, and Thorazine&reg; (DPT) for the Sedation of Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1995, 95(4):598-602.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30312/abstract-text/7700765/pubmed\" id=\"7700765\" target=\"_blank\">",
"        7700765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30312/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30312/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fernandes CM, &ldquo;Parenteral Chlorpromazine and a Meningitis Headache,&rdquo;",
"      <i>",
"       J Emerg Med",
"      </i>",
"      , 1995, 13(4):577-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30312/abstract-text/7594384/pubmed\" id=\"7594384\" target=\"_blank\">",
"        7594384",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gez E, Ben-Yosef R, Catane R, et al, &ldquo;Chlorpromazine and Dexamethasone Versus High-Dose Metoclopramide and Dexamethasone in Patients Receiving Cancer Chemotherapy, Particularly Cis-Platinum: A Prospective Randomized Crossover Study,&rdquo;",
"      <i>",
"       Oncology",
"      </i>",
"      , 1989, 46(3):150-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30312/abstract-text/2654792/pubmed\" id=\"2654792\" target=\"_blank\">",
"        2654792",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gez E, Brufman G, Kaufman B, et al, &ldquo;Methylprednisolone and Chlorpromazine in Patients Receiving Cancer Chemotherapy: A Prospective Nonrandomized Study,&rdquo;",
"      <i>",
"       J Chemother",
"      </i>",
"      , 1989, 1(2):140-3.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gill SS, Bronskill SE, Normand SL, et al, &ldquo;Antipsychotic Drug Use and Mortality in Older Adults With Dementia,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2007, 146(11):775-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30312/abstract-text/17548409/pubmed\" id=\"17548409\" target=\"_blank\">",
"        17548409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hutcheon AW, Palmer JB, Soukop M, et al, &ldquo;A Randomized Multicentre Single Blind Comparison of a Cannabinoid Antiemetic (Levonantradol) With Chlorpromazine in Patients Receiving Their First Cytotoxic Chemotherapy,&rdquo;",
"      <i>",
"       Eur J Cancer Clin Oncol",
"      </i>",
"      , 1983, 19(8):1087-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30312/abstract-text/6352278/pubmed\" id=\"6352278\" target=\"_blank\">",
"        6352278",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Knight ME and Roberts RJ, &ldquo;Phenothiazine and Butyrophenone Intoxication in Children,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1986, 33(2):299-309.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30312/abstract-text/2870459/pubmed\" id=\"2870459\" target=\"_blank\">",
"        2870459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lancelin F, Kraoul L, Flatischler N, et al, &ldquo;False-Positive Results in the Detection of Methadone in Urines of Patients Treated With Psychotropic Substances,&rdquo;",
"      <i>",
"       Clin Chem",
"      </i>",
"      , 2005, 51(11):2176-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30312/abstract-text/16244295/pubmed\" id=\"16244295\" target=\"_blank\">",
"        16244295",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipka LJ, Lathers CM, and Roberts J, &ldquo;Does Chlorpromazine Produce Cardiac Arrhythmia Via the Central Nervous System,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1988, 28(11):968-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30312/abstract-text/3149655/pubmed\" id=\"3149655\" target=\"_blank\">",
"        3149655",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mitchell AC and Brown KW, &ldquo;Chlorpromazine-Induced Retinopathy,&rdquo;",
"      <i>",
"       Br J Psychiatry",
"      </i>",
"      , 1995, 166(6):822-3.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moore TA, &ldquo;Schizophrenia Treatment Guidelines in the United States,&rdquo;",
"      <i>",
"       Clin Schizophr Relat Psychoses",
"      </i>",
"      , 2011, 5(1):40-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30312/abstract-text/21459738/pubmed\" id=\"21459738\" target=\"_blank\">",
"        21459738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health , &ldquo;Schizophrenia. Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Updated),&rdquo; National Clinical Practice Guideline Number 82, 2009:1-399. Available at  www.nice.org.uk/cg082",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olsen KM, Gulliksen M, and Christophersen AS, &ldquo;Metabolites of Chlorpromazine and Brompheniramine May Cause False-Positive Urine Amphetamine Results with Monoclonal EMIT D.A.U. Immunoassay,&rdquo;",
"      <i>",
"       Clin Chem",
"      </i>",
"      , 1992, 38(4):611-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30312/abstract-text/1568344/pubmed\" id=\"1568344\" target=\"_blank\">",
"        1568344",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oshika T, &ldquo;Ocular Adverse Effects of Neuropsychiatric Agents. Incidence and Management,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1995, 12(4):256-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30312/abstract-text/7646824/pubmed\" id=\"7646824\" target=\"_blank\">",
"        7646824",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peabody CA, Warner MD, Whiteford HA, et al, &ldquo;Neuroleptics and the Elderly,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1987, 35(3):233-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30312/abstract-text/2880887/pubmed\" id=\"2880887\" target=\"_blank\">",
"        2880887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Polishuk WZ and Kulcsar S, \"Effects of Chlorpromazine on Pituitary Function,\"",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 1956, 16(2):292-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30312/abstract-text/13286329/pubmed\" id=\"13286329\" target=\"_blank\">",
"        13286329",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rabins PV, Blacker D, Rovner BW, et al, &ldquo;American Psychiatric Association Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Second Edition,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(12 Suppl):5-56.  Available at file://psychiatryonline.org/guidelines.aspx",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30312/abstract-text/18340692/pubmed\" id=\"18340692\" target=\"_blank\">",
"        18340692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Relling MV, Mulhern RK, Fairclough D, et al, &ldquo;Chlorpromazine With and Without Lorazepam as Antiemetic Therapy in Children Receiving Uniform Chemotherapy,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1993, 123(5):811-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30312/abstract-text/8229497/pubmed\" id=\"8229497\" target=\"_blank\">",
"        8229497",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Risse SC and Barnes R, &ldquo;Pharmacologic Treatment of Agitation Associated With Dementia,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1986, 34(5):368-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30312/abstract-text/2870097/pubmed\" id=\"2870097\" target=\"_blank\">",
"        2870097",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosenberg MR and Green M, &ldquo;Neuroleptic Malignant Syndrome: Review of Response to Therapy,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1989, 149(9):1927-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30312/abstract-text/2673115/pubmed\" id=\"2673115\" target=\"_blank\">",
"        2673115",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saab GA, Shamseddine A, and Habbal Z, &ldquo;Prolonged Chlorpromazine Infusion as Antiemetic in Patients on Daily Cisplating Infusion. A Pilot Study,&rdquo;",
"      <i>",
"       Am J Clin Oncol",
"      </i>",
"      , 1988, 11(4):470-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30312/abstract-text/3407627/pubmed\" id=\"3407627\" target=\"_blank\">",
"        3407627",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saltz BL, Woerner MG, Kane JM, et al, &ldquo;Prospective Study of Tardive Dyskinesia Incidence in the Elderly,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1991, 266(17):2402-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30312/abstract-text/1681122/pubmed\" id=\"1681122\" target=\"_blank\">",
"        1681122",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schneeweiss S, Setoguchi S, Brookhart A, et al, &ldquo;Risk of Death Associated With the Use of Conventional Versus Atypical Antipsychotic Drugs Among Elderly Patients,&rdquo;",
"      <i>",
"       CMAJ",
"      </i>",
"      , 2007, 176(5): 627-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30312/abstract-text/17325327/pubmed\" id=\"17325327\" target=\"_blank\">",
"        17325327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seifert RD, &ldquo;Therapeutic Drug Monitoring: Psychotropic Drugs,&rdquo;",
"      <i>",
"       J Pharm Pract",
"      </i>",
"      , 1984, 6:403-16.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wiles DH, Orr MW, and Kolakowska T, \"Chlorpromazine Levels in Plasma and Milk of Nursing Mothers,\"",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1978, 5(3):272-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/38/30312/abstract-text/656275/pubmed\" id=\"656275\" target=\"_blank\">",
"        656275",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9252 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-37992F4EF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_38_30312=[""].join("\n");
var outline_f29_38_30312=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7290573\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150514\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150560\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150518\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150539\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150519\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150520\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150521\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150486\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150470\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150491\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150566\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150490\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150557\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150568\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150558\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150494\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150474\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150555\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150479\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150509\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10923687\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150527\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150496\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524451\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150484\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150487\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150497\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150473\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150493\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9252\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9252|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/11/20661?source=related_link\">",
"      Chlorpromazine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/35/21047?source=related_link\">",
"      Chlorpromazine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_38_30313="Cellular mechanisms of diastolic dysfunction";
var content_f29_38_30313=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cellular mechanisms of diastolic dysfunction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/38/30313/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/38/30313/contributors\">",
"     James P Morgan, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/38/30313/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/38/30313/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/38/30313/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/38/30313/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/38/30313/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-third of patients with symptomatic congestive heart failure have a normal ejection fraction and symptoms that are entirely or in large measure a result of diastolic dysfunction. Diastolic dysfunction is caused by one or more of the following abnormalities in cardiac structure:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypertrophy",
"     </li>",
"     <li>",
"      Fibrosis",
"     </li>",
"     <li>",
"      Infiltrative diseases",
"     </li>",
"     <li>",
"      Pericardial constriction",
"     </li>",
"     <li>",
"      Myocardial edema",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Functional cellular abnormalities of myocyte relaxation can also cause diastolic dysfunction, which is reversible and transient [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/1\">",
"     1",
"    </a>",
"    ]. Causes of impaired myocyte relaxation include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ischemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypoxia",
"     </li>",
"     <li>",
"      Cellular calcium overload",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ATP depletion",
"     </li>",
"     <li>",
"      Certain cardiovascular drugs, eg, digitalis",
"     </li>",
"     <li>",
"      The hypertrophy process itself which alters the contractile and metabolic phenotype.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The cellular mechanisms of myocardial relaxation are presented here. These mechanisms involve calcium and sodium movements that reverse the processes of excitation-contraction coupling and can be thought of as repolarization-relaxation coupling. The pathophysiology, clinical features, treatment, and prognosis of diastolic dysfunction are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15818?source=see_link\">",
"     \"Pathophysiology of diastolic heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diastolic heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EXCITATION-CONTRACTION AND REPOLARIZATION-RELAXATION COUPLING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs, metabolic processes, or pathologic conditions may exert a positive or negative inotropic effect by influencing the movement of and sensitivity to calcium as part of the excitation-contraction coupling process. On the other hand, a positive or negative lusitropic (relaxation-enhancing) effect can result from changes in repolarization-relaxation coupling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Role of calcium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid changes in the intracellular levels of free ionized calcium regulate the contraction and relaxation of cardiac muscle. The modulation of calcium levels during systole and diastole occurs at several sites within the cell [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/2\">",
"     2",
"    </a>",
"    ]. The sarcoplasmic reticulum (SR) plays a central role in regulating contraction and relaxation of mammalian cardiac muscle. The SR serves as a releasable Ca",
"    <sup>",
"     2+",
"    </sup>",
"    store and regulates intracellular calcium levels during",
"    <span class=\"nowrap\">",
"     contraction/relaxation",
"    </span>",
"    cycles. Its function is coordinated by a set of Ca",
"    <sup>",
"     2+",
"    </sup>",
"    handling proteins, primarily the ryanodine receptor 2 (RYR2), which activates calcium release, and by the sarco(endo)plasmic reticulum Ca",
"    <sup>",
"     2+",
"    </sup>",
"    ATPase pump (SERCA2), which governs calcium re-uptake by the SR [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contraction is initiated during myocyte activation. An inward calcium current occurs during the action potential, when the sarcolemmal voltage-dependent calcium channel opens, and calcium diffuses into the cell, driven by its 10,000-fold transmembrane concentration gradient (",
"    <a class=\"graphic graphic_figure graphicRef53118 \" href=\"UTD.htm?20/34/21025\">",
"     figure 1",
"    </a>",
"    ). This calcium influx triggers a much greater amount of calcium release from the SR via RYR2. Cytosolic calcium levels rise rapidly and calcium binds to its myofilament receptor on troponin C, activating contractile protein tension generation via the actin-myosin cross-bridge cycle (",
"    <a class=\"graphic graphic_figure graphicRef67388 \" href=\"UTD.htm?14/21/14673\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10632?source=see_link\">",
"     \"Excitation-contraction coupling in myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For complete myocyte relaxation to occur, the cytosol must be largely cleared of calcium so that calcium dissociates from troponin C, and all tension-generating actin-myosin bonds must be lysed. The diastolic clearance of cytosolic calcium requires ATP to fuel the SERCA2 and sarcolemma calcium ATPases, which transport calcium into the SR or across the sarcolemma, respectively (",
"    <a class=\"graphic graphic_algorithm graphicRef79802 \" href=\"UTD.htm?6/34/6702\">",
"     algorithm 1",
"    </a>",
"    ). Calcium removal may also occur via sodium-calcium exchange, a process of secondary active transport driven by the low intracellular sodium concentration.",
"   </p>",
"   <p>",
"    Cardiac contractility and lusitropy may be altered by changing either the availability of intracellular calcium for activation or the responsiveness of the myofilaments to intracellular calcium (",
"    <a class=\"graphic graphic_table graphicRef75235 \" href=\"UTD.htm?5/63/6141\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef63030 \" href=\"UTD.htm?6/50/6948\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The availability of intracellular calcium is regulated by the sarcolemma and sarcoplasmic reticulum; these processes can be functionally monitored by means of the action potential and calcium transient, respectively (",
"      <a class=\"graphic graphic_figure graphicRef66739 \" href=\"UTD.htm?38/39/39549\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Calcium responsiveness is controlled by the myofilaments and the regulatory troponin-tropomyosin complex attached to actin and the myofilaments, actin and myosin (",
"      <a class=\"graphic graphic_figure graphicRef67388 \" href=\"UTD.htm?14/21/14673\">",
"       figure 2",
"      </a>",
"      ). These components can be functionally assessed by the calcium sensitivity and maximal calcium-activated force (Fmax) of fibers rendered hyperpermeable to calcium [",
"      <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Abnormal function at any one of these multiple sites can lead to systolic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/2,4,6\">",
"     2,4,6",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef74126 \" href=\"UTD.htm?27/14/27886\">",
"     figure 5",
"    </a>",
"    ). In particular, diastolic dysfunction can result from excessive calcium entry into the cytosol, a decrease in calcium efflux, or from inadequate calcium reuptake by the sarcoplasmic reticulum during diastole; it does not seem to be due to an excessive calcium influx via slow \"L\"-type calcium channels [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/7\">",
"     7",
"    </a>",
"    ]. Support for this comes from a study of myocardial tissue obtained from patients with end-stage congestive heart failure at the time of transplant; diastolic dysfunction occurred in hearts with a decreased sarcoplasmic reticulum calcium ATPase and unchanged sodium-calcium exchange while preserved diastolic function was seen when there was an increased expression of the sodium-calcium exchanger [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/8\">",
"     8",
"    </a>",
"    ]. Additionally, an animal study found that diastolic function could be improved by adenoviral gene transfer of sarcoplasmic reticulum calcium ATPase [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased intracellular calcium can directly impair diastolic relaxation by persistent activation of the actin-myosin cross-bridge interaction if calcium is not adequately cleared from the cytosol. Excessive calcium may also exert an indirect effect by reducing phosphocreatine and ATP, and increasing adenosine diphosphate, (ADP). These indirect effects result from enhanced activity of calcium-activated ATPases, such as the sarcoplasmic reticulum and sarcolemma calcium pumps and other ATPases [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/10\">",
"     10",
"    </a>",
"    ]. The changes in PCR, ATP, and ADP impair myocyte relaxation by causing cross-bridges to lock in a rigor bond position.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cyclic AMP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excitation-contraction coupling in the mammalian heart is modulated by an important second messenger, cyclic adenosine monophosphate (AMP) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/2\">",
"     2",
"    </a>",
"    ]. This nucleotide activates a series of protein kinases, which in turn phosphorylate proteins at several subcellular sites, including the sarcolemma, the sarcoplasmic reticulum (SR), and the troponin-tropomyosin regulatory complex on the myofilaments. Phosphorylation of the calcium channels in the sarcolemma increases calcium entry and force generation; phosphorylation of phospholamban on the SR and troponin I on the regulatory complex of the contractile elements enhances calcium resequestration and diastolic relaxation. This important pathway is initiated in vivo by activation of beta 1- and beta 2-adrenergic receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10632?source=see_link\">",
"     \"Excitation-contraction coupling in myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other second messengers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other second messengers in the heart may modulate excitation-contraction coupling. These include inositol triphosphate, which can induce the release of calcium from the sarcoplasmic reticulum, and diacylglycerol, which can activate various enzymatic processes including myosin light chain phosphorylation and sodium-hydrogen exchange (",
"    <a class=\"graphic graphic_figure graphicRef70144 \" href=\"UTD.htm?19/31/19966\">",
"     figure 6",
"    </a>",
"    ). However, the role of these other second messengers in the heart remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inotropic and lusitropic mechanisms can be divided into several types [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef74126 \" href=\"UTD.htm?27/14/27886\">",
"     figure 5",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those that are \"upstream\" from troponin C and modulate the availability of free calcium ions for activation of the contractile apparatus",
"     </li>",
"     <li>",
"      Those that are \"downstream\" and affect the ability of the myofilaments to respond to any given level of occupancy of the calcium receptor sites on troponin C",
"     </li>",
"     <li>",
"      Those that change in the affinity of troponin C for calcium",
"     </li>",
"     <li>",
"      Those that change the rate of energy use or supply to the myocytes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ABNORMAL CALCIUM MODULATION IN HEART DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal modulation of intracellular calcium has been proposed as a major mechanism underlying the systolic and diastolic dysfunction that develops with cardiac hypertrophy, heart failure, and ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Systole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systolic force generation is depressed in most models of heart failure, but this change does not always correlate with decreased availability of calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. As an example, in an animal model of right ventricular pressure-overload hypertrophy with failure, systolic force generation is depressed but intracellular calcium levels are normal [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/18\">",
"     18",
"    </a>",
"    ]. The major abnormality appears to be in the cardiac interstitium where significant changes occur in connective tissue content, which impairs systolic force generation. However, there is an excellent correlation between systolic dysfunction and decreased availability of calcium in cardiac muscle in other animal models of heart failure such as end-stage dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/19,20\">",
"     19,20",
"    </a>",
"    ], diabetes with heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/21\">",
"     21",
"    </a>",
"    ], and postmyocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diastole",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a highly positive correlation between end-diastolic calcium levels and diastolic relaxation abnormalities. The duration of diastole is prolonged in most models of congestive heart failure, a change that correlates with a prolongation of the intracellular calcium transient [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/16\">",
"     16",
"    </a>",
"    ]. However, marked increases in systolic and diastolic calcium occur in myocardial ischemia and appear to be uncoupled from force production which falls to very low levels [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Thus, in ischemia, decreased myofilament calcium responsiveness may affect both systolic force generation and diastolic relaxation.",
"   </p>",
"   <p>",
"    In hypertrophic cardiomyopathy, systolic function is normal or hyperdynamic, but diastolic relaxation may become so abnormally slow that complete relaxation between contractions is prevented. At rapid heart rates, this can produce elevated end-diastolic calcium levels and mechanical dysfunction resulting from fusion of the prolonged calcium transients and contractions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three characteristic signatures of congestive heart failure have been consistently noted in physiologic studies of human heart muscle loaded with the calcium indicator aequorin [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An abnormal second component in the calcium signal [",
"      <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/26\">",
"       26",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reversal of the normal positive staircase of the force-frequency relationship caused by abnormal calcium restitution processes",
"     </li>",
"     <li>",
"      A depressed response to most inotropic agonists that depend upon cyclic AMP generation to produce their cellular response [",
"      <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/29\">",
"       29",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Agents that increase intracellular calcium, such as digitalis, exacerbate diastolic functional abnormalities, whereas those that lower intracellular calcium, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , ameliorate them. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pharmacologic studies have shown that cyclic AMP levels are depressed in failing human myocardium due to reduced adenylyl cyclase activity; this abnormality may contribute to the alterations in calcium modulation and may be largely responsible for the presence of diastolic relaxation abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Interventions that increase intracellular cyclic AMP concentrations in myopathic human myocardium reverse or significantly ameliorate the diastolic dysfunction that is present [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial ischemia may be associated with a reversible increase in diastolic chamber stiffness both in patients with angina and in experimental models of ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Two mechanisms have been proposed as the cause of this increased chamber stiffness, but their relative importance remains controversial:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A rise in intracellular calcium, impaired intracellular reuptake of calcium, and a consequent increase in calcium-activated cross-bridge cycling and tension development [",
"      <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/23,35-38\">",
"       23,35-38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cross-bridges may lock in the rigor state due to a reduction in ATP and creatine phosphate levels or an elevation in ADP levels [",
"      <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/39-43\">",
"       39-43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During \"demand ischemia,\" when myocardial oxygen demand is increased in excess of coronary flow capability (as occurs during stress-induced angina), increased diastolic stiffness appears to be due to rigor-state cross-bridge formation rather than increased calcium-activated diastolic tension [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/44-47\">",
"     44-47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SARCOLEMMAL RECEPTORS AND MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardiac sarcolemma is a complex structure that contains multiple receptors (adrenergic and other), channels, exchangers, and pumps that are necessary for maintaining cellular calcium homeostasis (",
"    <a class=\"graphic graphic_figure graphicRef53118 \" href=\"UTD.htm?20/34/21025\">",
"     figure 1",
"    </a>",
"    ). Aspects of normal sarcolemmal function are impaired in the failing heart.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Adrenergic receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both beta-l and beta-2 adrenoceptors, coupled with G proteins, are present in human atrial and ventricular myocardium, and both appear to increase tissue levels of cyclic AMP [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. In the nonfailing ventricle, beta-1 receptor density dominates, with the beta-2 and alpha-receptors constituting less than 30 percent of the total [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. In contrast, in the failing heart, there is a selection decrease in the beta-1 fraction by 60 to 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. These changes in receptor populations may vary with the etiology of heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A third beta-adrenergic receptor (beta-3) is also present in the myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/55\">",
"     55",
"    </a>",
"    ]. Activation of this receptor reduces inotropic activity; such an effect could explain in part the improvement in contractility that may be seen with beta blocker therapy in some patients with congestive heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Calcium binding sites",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the downregulation of beta -1 adrenergic receptors in heart failure, the calcium antagonist binding sites are not significantly altered in failing left ventricular tissue from patients with idiopathic dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Sodium-calcium exchange",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been an increasing appreciation that the level of intracellular sodium, acting by means of sodium-calcium exchange, is an important determinant of intracellular calcium (",
"    <a class=\"graphic graphic_figure graphicRef66739 \" href=\"UTD.htm?38/39/39549\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/57\">",
"     57",
"    </a>",
"    ]. The failing heart may be associated with increased intracellular sodium levels due perhaps to reduced activity of the Na-K-ATPase pump that extrudes sodium from the cell. Increased cell sodium decreases the transcellular sodium gradient which drives sodium-calcium exchange; the reduction in sodium-calcium exchange impairs calcium extrusion from the myocardial cell, possibly resulting in prolongation of the action potential and impaired myocyte relaxation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Calcium ATPase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The calcium ATPase of the cardiac sarcolemma appears to be important for the \"fine tuning\" of calcium homeostasis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/60\">",
"     60",
"    </a>",
"    ]. To date, specific abnormalities associated with dysfunction of this relatively low capacity pump have not been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Sarcoplasmic reticulum",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sarcoplasmic reticulum (SR) is the most important intracellular store of calcium in the mammalian heart and plays a primary part in regulating both contraction and relaxation (",
"    <a class=\"graphic graphic_figure graphicRef62842 \" href=\"UTD.htm?8/14/8417\">",
"     figure 7",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10632?source=see_link\">",
"     \"Excitation-contraction coupling in myocardium\"",
"    </a>",
"    .) Drugs affecting calcium release and reuptake by the SR have profound effects on diastolic relaxation (",
"    <a class=\"graphic graphic_table graphicRef75235 \" href=\"UTD.htm?5/63/6141\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/61\">",
"     61",
"    </a>",
"    ]. As an example, caffeine, a complex drug that prolongs contraction and delays relaxation, appears to act predominantly by blocking the ATP-dependent calcium pump of the SR that functions to resequester intracellular calcium.",
"   </p>",
"   <p>",
"    Some, but not all, studies have shown decreased calcium uptake rates by the sarcoplasmic reticulum in myopathic human myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/62\">",
"     62",
"    </a>",
"    ]. In addition, experimental studies have shown a relative diminution in the density of SR calcium pumps in pressure overload-induced cardiac hypertrophy, an abnormality that could explain the slow velocity of relaxation of severely hypertrophied hearts [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/63\">",
"     63",
"    </a>",
"    ]. Abnormal calcium modulation by the sarcoplasmic reticulum may contribute to the abnormal frequency-response relationship that is one of the characteristics of failing human myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ALTERED MYOFILAMENT CALCIUM RESPONSIVENESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac muscle from patients with heart failure of all severities has a lower myofibrillar protein content than muscle from normal hearts [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/65\">",
"     65",
"    </a>",
"    ]. This observation suggests that a reduction in the amount of myofibrillar protein in ventricular tissue may be a pivotal event in the progression of heart disease to end-stage failure; it may also be related to the development of diastolic dysfunction.",
"   </p>",
"   <p>",
"    In addition to changes in calcium availability, cardiac contractility can be regulated by changing the myofilament responsiveness to calcium (",
"    <a class=\"graphic graphic_figure graphicRef63030 \" href=\"UTD.htm?6/50/6948\">",
"     figure 3",
"    </a>",
"    ). Such an effect could occur through altering the affinity of calcium binding to its receptor protein, troponin C, or by some other action on the myofilaments themselves, such as phosphorylation of the myosin light chains or the C proteins of the myosin thick filaments [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The applicability of this hypothesis to human disease is uncertain. Several studies have found that end-stage heart failure in humans is not associated with changes in basal myofibrillar calcium sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. However, it is possible that the effects of pharmacologic agents on myofibrillar calcium sensitivity can be altered in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ALTERATION OF EXCITATION-CONTRACTION AND REPOLARIZATION-RELAXATION COUPLING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analysis of the excitation-contraction and repolarization-relaxation coupling pathways predicts that alterations which increase diastolic cytosolic calcium levels may cause diastolic dysfunction because of persistent calcium-activated tension throughout diastole. Conversely, interventions that reduce diastolic cytosolic calcium levels should have a positive lusitropic effect and the potential to ameliorate diastolic dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Role of adenosine triphosphate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The beginning of an ischemic or hypoxic contracture is associated with a fall of cell ATP below a critical level. Such a decrease in ATP availability, which causes actin-myosin crossbridges to \"lock\" in a noncycling rigor state, was proposed as the mechanism for the initiation of increased diastolic chamber stiffness [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/40,71\">",
"     40,71",
"    </a>",
"    ]. Support for this comes from a study in which magnetic resonance imaging and phosphorous-31 magnetic resonance spectroscopy were performed at rest and during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress testing in 24 patients with and without hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/72\">",
"     72",
"    </a>",
"    ]. Compared to normal controls, patients with hypertension showed significant alterations at rest in high energy phosphate metabolism with a decrease in creatine kinase activity, a lower total creatine content, and an increase in intracellular inorganic phosphate levels; these changes, which correlated with impaired diastolic function, are similar to what is seen in the normal human heart during severe myocardial stress.",
"   </p>",
"   <p>",
"    ATP availability can influence the rate and extent of myocardial relaxation in several ways (",
"    <a class=\"graphic graphic_figure graphicRef78403 \" href=\"UTD.htm?15/7/15487\">",
"     figure 8",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ATP is required to fuel the ion pumps that directly remove calcium from the cytosol during diastole: the sarcoplasmic reticular calcium- ATPase; and the sarcolemmal calcium extrusion pump (sarcolemmal calcium-ATPase)",
"     </li>",
"     <li>",
"      ATP provides energy for the sarcolemmal sodium pump (Na-K-ATPase). An active sodium pump is critical for achieving myocyte relaxation because the intracellular sodium concentration regulates intracellular calcium levels via sarcolemmal sodium-calcium exchange.",
"     </li>",
"     <li>",
"      ATP influences myocardial relaxation directly at the level of the myofilaments by interacting with actomyosin to cause its dissociation to actin and myosin, a step critical to relaxation (",
"      <a class=\"graphic graphic_figure graphicRef51291 \" href=\"UTD.htm?18/40/19074\">",
"       figure 9",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The interaction of ATP with the contractile proteins is complex because ATP has a dual role, being required for both contraction and relaxation. If there is a small amount of ATP depletion, actin-myosin complexes can still form because of the high affinity of the myosin head for ATP, but the dissociation of actin and myosin is reduced since this requires higher concentrations of ATP. Thus, the initial net effect of ATP depletion is to cause inadequate relaxation or diastolic dysfunction. In addition, there is a synergistic interaction between ATP depletion and an elevation in cytosolic calcium to promote diastolic dysfunction (",
"    <a class=\"graphic graphic_figure graphicRef74126 \" href=\"UTD.htm?27/14/27886\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Role of glycolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further evidence that altered ATP levels have a critical role in causing ischemic diastolic dysfunction comes from studies of ischemic glycolysis. During conditions of oxygen supply limitation such as ischemia, the glycolytic pathway becomes a relatively more important source of ATP synthesis because of its ability to achieve ATP synthesis anaerobically. In general, the rate of development of ischemic contracture or diastolic dysfunction is inversely related to the activity of the glycolytic pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/73-76\">",
"     73-76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glycolysis also plays an important role in the diastolic function of certain forms of pressure-overload hypertrophy. Inhibition of glycolysis in hypertrophied hearts resulted in a much greater impairment of diastolic relaxation than in controls [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. On the other hand, the exaggerated ischemic diastolic chamber stiffness in hypertrophied hearts can be attenuated by providing abundant glycolytic substrate [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These results are consistent with the hypothesis that the glycolytic pathway may provide a small but critically localized pool of ATP, which may have a high turnover rate relative to its pool size [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/80\">",
"     80",
"    </a>",
"    ]. Provision of glucose to rat hearts during low-flow ischemia protects against ischemic diastolic dysfunction; this effect is associated with enhanced sarcolemmal Na-K-ATPase activity which prevents an increase in intracellular sodium during ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/10\">",
"     10",
"    </a>",
"    ]. Since intracellular sodium excess can lead to cell calcium accumulation (due to reduced sodium-calcium exchange), glucose probably also protected against calcium overload.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Digitalis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Digitalis glycosides inhibit the sarcolemmal sodium-potassium ATPase pump, causing an increase in intracellular sodium and ultimately an increase in intracellular calcium via the mechanism described above. The elevation in intracellular calcium is believed to be responsible for the positive inotropic effect of the digitalis glycosides but can also cause diastolic dysfunction due to diastolic cytosolic calcium overload. This is most likely to occur when diastolic calcium removal is impaired, as with hypoxia or ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/81,82\">",
"     81,82",
"    </a>",
"    ], or when the myocyte is under an additional cation load during tachycardia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Beta-adrenergic stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate manipulation of excitation-contraction and repolarization-relaxation coupling can significantly improve hypoxic diastolic function [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/83\">",
"     83",
"    </a>",
"    ]. The beta-adrenergic agonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    exerts its inotropic effect by increasing systolic calcium availability due to an increase in calcium entry via the sarcolemmal calcium channel; its lusitropic action is caused by both an enhanced rate of SR calcium reuptake by a phospholamban-mediated mechanism, and reduced troponin sensitivity to calcium.",
"   </p>",
"   <p>",
"    The simultaneous administration of the calcium channel blocker",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    at a dose that blocks the inotropic effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    does not alter its lusitropic actions. This combination regimen results in a net lusitropic effect, increasing both the rate and extent of left ventricular relaxation with and without hypoxia, partially eliminating the exaggerated hypoxic diastolic dysfunction associated with ventricular hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Role of angiotensin II and angiotensin converting enzyme inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum angiotensin II concentrations are increased in congestive heart failure, and therapy with angiotensin converting enzyme (ACE) inhibitors improves heart failure symptoms and increases survival. The benefit of ACE inhibition has been attributed to diminished angiotensin II effect on the peripheral circulation, reducing systemic vascular resistance and therefore afterload. Angiotensin II also may directly impair myocardial relaxation, especially in the setting of hypertrophy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ischemia. Reversal of this effect with ACE inhibitors or angiotensin II receptor antagonists may be an important mechanism of benefit in patients with heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14008?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in heart failure: Mechanisms of action\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to systemic activation of the renin-angiotensin system, there is now substantial evidence supporting the presence of an endogenous renin-angiotensin system in the heart which may contribute to the development of diastolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/84-86\">",
"     84-86",
"    </a>",
"    ]. As an example, the following observations have been made in hypertrophied hearts:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An infusion of angiotensin I resulted in an immediate impairment in diastolic relaxation which was not observed in nonhypertrophied hearts [",
"      <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/86\">",
"       86",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      They have a greater capacity to convert angiotensin I to angiotensin II [",
"      <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/86\">",
"       86",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      They show exaggerated diastolic dysfunction during low-flow ischemia and a greater degree of ischemic diastolic dysfunction in response after exposure to angiotensin II [",
"      <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/87\">",
"       87",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      An ACE inhibitor significantly reduces the ischemia-mediated exaggeration in diastolic dysfunction in the hypertrophied, but not the nonhypertrophied, heart [",
"      <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Angiotensin II also has a deleterious effect on ischemic diastolic function in the absence of hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms by which angiotensin II impairs myocardial relaxation are not completely defined. In one study, the induction of ischemic diastolic dysfunction was independent of changes of ATP levels, glycolytic rate, or ischemic coronary blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/37\">",
"     37",
"    </a>",
"    ]. The most important effects may be an elevation in intracellular pH and enhanced myofilament sensitivity to calcium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36825?source=see_link\">",
"     \"Actions of angiotensin II on the heart\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     ROLE OF TITIN IN DIASTOLIC FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Titin is a giant myocyte protein that spans half the sarcomere and plays two critical roles in diastolic function: a recoil spring mechanism and a desensitizer of the myofilaments to calcium.",
"   </p>",
"   <p>",
"    Titin is compressed when the myocyte shortens during systole. At the beginning of cell relaxation, when the actin-myosin crossbridges detach and active shortening tension begins to dissipate, the compressed titin forcefully expands and generates an intracellular \"restoring force\" that relengthens the sarcomere and myocyte [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/88\">",
"     88",
"    </a>",
"    ]. This restoring force creates a substantial early diastolic ventricular elastic recoil that generates a negative LV pressure that sucks blood across the mitral valve and facilitates LV filling at low LV and left atrial diastolic (filling) pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The early diastolic elastic recoil is amplified during exercise when greater systolic myocyte shortening causes greater titin compression; this is a critical mechanism that enhances LV diastolic filling during exercise without an increase in left atrial and pulmonary capillary pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to acting as a recoil spring, titin, in its compressed state, also interacts with the actin-myosin filament to desensitize it to calcium. Thus, the marked titin compression at end-systole facilitates both the detachment of the actin-myosin crossbridge and cell relengthening by the two additive actions of desensitization and elastic recoil [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/88-90\">",
"     88-90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations in the titin gene have been associated with a familial dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/38/30313/abstract/91\">",
"     91",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=see_link&amp;anchor=H685023#H685023\">",
"     \"Genetics of dilated cardiomyopathy\", section on 'Sarcomere genes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30857764\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diastolic dysfunction is caused by structural and functional abnormalities. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alterations in excitation-contraction coupling can have positive or negative inotropic effects. Alterations in repolarization-relaxation coupling can have positive or negative lusitropic (relaxation-enhancing) effects. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Excitation-contraction and repolarization-relaxation coupling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abnormal modulation of intracellular calcium has been proposed as a major mechanism underlying systolic and diastolic dysfunction occurring with cardiac hypertrophy, heart failure, and ischemia. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Abnormal calcium modulation in heart disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cardiac sarcolemma is a complex structure that contains multiple receptors (adrenergic and other), channels, exchangers, and pumps that are necessary for maintaining cellular calcium homeostasis (",
"      <a class=\"graphic graphic_figure graphicRef53118 \" href=\"UTD.htm?20/34/21025\">",
"       figure 1",
"      </a>",
"      ). Aspects of normal sarcolemmal function are impaired in the failing heart. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Sarcolemmal receptors and mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiac muscle from patients with heart failure of all severities has a lower myofibrillar protein content than muscle from normal hearts. This observation suggests that a reduction in the amount of myofibrillar protein in ventricular tissue may be a pivotal event in the progression of heart disease to end-stage failure; it may also be related to the development of diastolic dysfunction. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Altered myofilament calcium responsiveness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alterations that increase diastolic cytosolic calcium levels may cause diastolic dysfunction because of persistent calcium-activated tension throughout diastole. Conversely, interventions that reduce diastolic cytosolic calcium levels should have a positive lusitropic effect and the potential to ameliorate diastolic dysfunction. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Alteration of excitation-contraction and repolarization-relaxation coupling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Titin is a giant myocyte protein that spans half of the sarcomere and plays two critical roles in diastolic function: a recoil spring mechanism and a desensitizer of the myofilaments to calcium. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Role of titin in diastolic function'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/1\">",
"      Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation 2002; 105:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/2\">",
"      Morgan JP. Abnormal intracellular modulation of calcium as a major cause of cardiac contractile dysfunction. N Engl J Med 1991; 325:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/3\">",
"      Periasamy M, Janssen PM. Molecular basis of diastolic dysfunction. Heart Fail Clin 2008; 4:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/4\">",
"      Cheng H, Lederer MR, Xiao RP, et al. Excitation-contraction coupling in heart: new insights from Ca2+ sparks. Cell Calcium 1996; 20:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/5\">",
"      Blinks JR, Endoh M. Modification of myofibrillar responsiveness to Ca++ as an inotropic mechanism. Circulation 1986; 73:III85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/6\">",
"      Katz AM. Interplay between inotropic and lusitropic effects of cyclic adenosine monophosphate on the myocardial cell. Circulation 1990; 82:I7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/7\">",
"      Applegate RJ, Walsh RA, O'Rourke RA. Effects of nifedipine on diastolic function during brief periods of flow-limiting ischemia in the conscious dog. Circulation 1987; 76:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/8\">",
"      Hasenfuss G, Schillinger W, Lehnart SE, et al. Relationship between Na+-Ca2+-exchanger protein levels and diastolic function of failing human myocardium. Circulation 1999; 99:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/9\">",
"      Schmidt U, del Monte F, Miyamoto MI, et al. Restoration of diastolic function in senescent rat hearts through adenoviral gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase. Circulation 2000; 101:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/10\">",
"      Cross HR, Radda GK, Clarke K. The role of Na+/K+ ATPase activity during low flow ischemia in preventing myocardial injury: a 31P, 23Na and 87Rb NMR spectroscopic study. Magn Reson Med 1995; 34:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/11\">",
"      Kaumann A, Bartel S, Molenaar P, et al. Activation of beta2-adrenergic receptors hastens relaxation and mediates phosphorylation of phospholamban, troponin I, and C-protein in ventricular myocardium from patients with terminal heart failure. Circulation 1999; 99:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/12\">",
"      Katz AM. Energy requirements of contraction and relaxation: implications for inotropic stimulation of the failing heart. Basic Res Cardiol 1989; 84 Suppl 1:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/13\">",
"      Hein S, Schaper J. Pathogenesis of dilated cardiomyopathy and heart failure: insights from cell morphology and biology. Curr Opin Cardiol 1996; 11:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/14\">",
"      Wagoner LE, Walsh RA. The cellular pathophysiology of progression to heart failure. Curr Opin Cardiol 1996; 11:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/15\">",
"      Davies CH, Harding SE, Poole-Wilson PA. Cellular mechanisms of contractile dysfunction in human heart failure. Eur Heart J 1996; 17:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/16\">",
"      Perreault CL, Bing OH, Brooks WW, et al. Differential effects of cardiac hypertrophy and failure on right versus left ventricular calcium activation. Circ Res 1990; 67:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/17\">",
"      Perreault CL, Hague NL, Ransil BJ, Morgan JP. The effects of cocaine on intracellular Ca2+ handling and myofilament Ca2+ responsiveness of ferret ventricular myocardium. Br J Pharmacol 1990; 101:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/18\">",
"      Gwathmey JK, Morgan JP. Altered calcium handling in experimental pressure-overload hypertrophy in the ferret. Circ Res 1985; 57:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/19\">",
"      Bentivegna LA, Ablin LW, Kihara Y, Morgan JP. Altered calcium handling in left ventricular pressure-overload hypertrophy as detected with aequorin in the isolated, perfused ferret heart. Circ Res 1991; 69:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/20\">",
"      Wikman-Coffelt J, Stefenelli T, Wu ST, et al. [Ca2+]i transients in the cardiomyopathic hamster heart. Circ Res 1991; 68:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/21\">",
"      Belke DD, Dillmann WH. Altered cardiac calcium handling in diabetes. Curr Hypertens Rep 2004; 6:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/22\">",
"      Litwin SE, Morgan JP. Captopril enhances intracellular calcium handling and beta-adrenergic responsiveness of myocardium from rats with postinfarction failure. Circ Res 1992; 71:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/23\">",
"      Kihara Y, Grossman W, Morgan JP. Direct measurement of changes in intracellular calcium transients during hypoxia, ischemia, and reperfusion of the intact mammalian heart. Circ Res 1989; 65:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/24\">",
"      Mohabir R, Lee HC, Kurz RW, Clusin WT. Effects of ischemia and hypercarbic acidosis on myocyte calcium transients, contraction, and pHi in perfused rabbit hearts. Circ Res 1991; 69:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/25\">",
"      Steenbergen C, Murphy E, Levy L, London RE. Elevation in cytosolic free calcium concentration early in myocardial ischemia in perfused rat heart. Circ Res 1987; 60:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/26\">",
"      Gwathmey JK, Copelas L, MacKinnon R, et al. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res 1987; 61:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/27\">",
"      Gwathmey JK, Warren SE, Briggs GM, et al. Diastolic dysfunction in hypertrophic cardiomyopathy. Effect on active force generation during systole. J Clin Invest 1991; 87:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/28\">",
"      Hasenfuss G, Reinecke H, Studer R, et al. Calcium cycling proteins and force-frequency relationship in heart failure. Basic Res Cardiol 1996; 91 Suppl 2:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/29\">",
"      Feldman MD, Copelas L, Gwathmey JK, et al. Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 1987; 75:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/30\">",
"      Erdmann E. The effectiveness of inotropic agents in isolated cardiac preparations from the human heart. Klin Wochenschr 1988; 66:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/31\">",
"      N&auml;bauer M, B&ouml;hm M, Brown L, et al. Positive inotropic effects in isolated ventricular myocardium from non-failing and terminally failing human hearts. Eur J Clin Invest 1988; 18:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/32\">",
"      Fifer MA, Bourdillon PD, Lorell BH. Altered left ventricular diastolic properties during pacing-induced angina in patients with aortic stenosis. Circulation 1986; 74:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/33\">",
"      Carroll JD, Hess OM, Hirzel HO, Krayenbuehl HP. Exercise-induced ischemia: the influence of altered relaxation on early diastolic pressures. Circulation 1983; 67:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/34\">",
"      Bronzwaer JG, de Bruyne B, Ascoop CA, Paulus WJ. Comparative effects of pacing-induced and balloon coronary occlusion ischemia on left ventricular diastolic function in man. Circulation 1991; 84:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/35\">",
"      Apstein CS, Grossman W. Opposite initial effects of supply and demand ischemia on left ventricular diastolic compliance: the ischemia-diastolic paradox. J Mol Cell Cardiol 1987; 19:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/36\">",
"      Eberli FR, Weinberg EO, Grice WN, et al. Protective effect of increased glycolytic substrate against systolic and diastolic dysfunction and increased coronary resistance from prolonged global underperfusion and reperfusion in isolated rabbit hearts perfused with erythrocyte suspensions. Circ Res 1991; 68:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/37\">",
"      Mochizuki T, Eberli FR, Apstein CS, Lorell BH. Exacerbation of ischemic dysfunction by angiotensin II in red cell-perfused rabbit hearts. Effects on coronary flow, contractility, and high-energy phosphate metabolism. J Clin Invest 1992; 89:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/38\">",
"      Wexler LF, Weinberg EO, Ingwall JS, Apstein CS. Acute alterations in diastolic left ventricular chamber distensibility: mechanistic differences between hypoxemia and ischemia in isolated perfused rabbit and rat hearts. Circ Res 1986; 59:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/39\">",
"      Katz AM, Tada M. The \"stone heart\": a challenge to the biochemist. Am J Cardiol 1972; 29:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/40\">",
"      Hearse DJ, Garlick PB, Humphrey SM. Ischemic contracture of the myocardium: mechanisms and prevention. Am J Cardiol 1977; 39:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/41\">",
"      Ventura-Clapier R, Veksler V. Myocardial ischemic contracture. Metabolites affect rigor tension development and stiffness. Circ Res 1994; 74:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/42\">",
"      Yamashita H, Sata M, Sugiura S, et al. ADP inhibits the sliding velocity of fluorescent actin filaments on cardiac and skeletal myosins. Circ Res 1994; 74:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/43\">",
"      Tian R, Christe ME, Spindler M, et al. Role of MgADP in the development of diastolic dysfunction in the intact beating rat heart. J Clin Invest 1997; 99:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/44\">",
"      Varma N, Eberli FR, Apstein CS. Increased diastolic chamber stiffness during demand ischemia: response to quick length change differentiates rigor-activated from calcium-activated tension. Circulation 2000; 101:2185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/45\">",
"      Eberli FR, Str&ouml;mer H, Ferrell MA, et al. Lack of direct role for calcium in ischemic diastolic dysfunction in isolated hearts. Circulation 2000; 102:2643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/46\">",
"      Varma N, Eberli FR, Apstein CS. Left ventricular diastolic dysfunction during demand ischemia: rigor underlies increased stiffness without calcium-mediated tension. Amelioration by glycolytic substrate. J Am Coll Cardiol 2001; 37:2144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/47\">",
"      Varma N, Morgan JP, Apstein CS. Mechanisms underlying ischemic diastolic dysfunction: relation between rigor, calcium homeostasis, and relaxation rate. Am J Physiol Heart Circ Physiol 2003; 284:H758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/48\">",
"      Lefkowitz RJ, Hausdorff WP, Caron MG. Role of phosphorylation in desensitization of the beta-adrenoceptor. Trends Pharmacol Sci 1990; 11:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/49\">",
"      Collins S, Bolanowski MA, Caron MG, Lefkowitz RJ. Genetic regulation of beta-adrenergic receptors. Annu Rev Physiol 1989; 51:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/50\">",
"      Brodde OE. Beta 1- and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev 1991; 43:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/51\">",
"      Bristow MR, Hershberger RE, Port JD, et al. Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 1990; 82:I12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/52\">",
"      Bristow MR, Ginsburg R, Umans V, et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 1986; 59:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/53\">",
"      Altschuld RA, Starling RC, Hamlin RL, et al. Response of failing canine and human heart cells to beta 2-adrenergic stimulation. Circulation 1995; 92:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/54\">",
"      Bristow MR, Anderson FL, Port JD, et al. Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991; 84:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/55\">",
"      Gauthier C, Tavernier G, Charpentier F, et al. Functional beta3-adrenoceptor in the human heart. J Clin Invest 1996; 98:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/56\">",
"      Rasmussen RP, Minobe W, Bristow MR. Calcium antagonist binding sites in failing and nonfailing human ventricular myocardium. Biochem Pharmacol 1990; 39:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/57\">",
"      Kaczorowski GJ, Slaughter RS, King VF, Garcia ML. Inhibitors of sodium-calcium exchange: identification and development of probes of transport activity. Biochim Biophys Acta 1989; 988:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/58\">",
"      Schouten VJ, ter Keurs HE, Quaegebeur JM. Influence of electrogenic Na/Ca exchange on the action potential in human heart muscle. Cardiovasc Res 1990; 24:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/59\">",
"      Wankerl M, Schwartz K. Calcium transport proteins in the nonfailing and failing heart: gene expression and function. J Mol Med (Berl) 1995; 73:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/60\">",
"      Caroni P, Carafoli E. An ATP-dependent Ca2+-pumping system in dog heart sarcolemma. Nature 1980; 283:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/61\">",
"      Sutko JL, Ito K, Kenyon JL. Ryanodine: a modifier of sarcoplasmic reticulum calcium release in striated muscle. Fed Proc 1985; 44:2984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/62\">",
"      Dillmann WH. Regulation of expression of cardiac sarcoplasmic reticulum proteins under pathophysiological conditions. Mol Cell Biochem 1996; 157:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/63\">",
"      de la Bastie D, Levitsky D, Rappaport L, et al. Function of the sarcoplasmic reticulum and expression of its Ca2(+)-ATPase gene in pressure overload-induced cardiac hypertrophy in the rat. Circ Res 1990; 66:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/64\">",
"      Gwathmey JK, Slawsky MT, Hajjar RJ, et al. Role of intracellular calcium handling in force-interval relationships of human ventricular myocardium. J Clin Invest 1990; 85:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/65\">",
"      ter Keurs HE. Heart failure and Starling's Law of the heart. Can J Cardiol 1996; 12:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/66\">",
"      R&uuml;egg JC, Morano I. Calcium-sensitivity modulation of cardiac myofibrillar proteins. J Cardiovasc Pharmacol 1989; 14 Suppl 3:S20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/67\">",
"      Morano I, Arndt H, G&auml;rtner C, R&uuml;egg JC. Skinned fibers of human atrium and ventricle: myosin isoenzymes and contractility. Circ Res 1988; 62:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/68\">",
"      Hajjar RJ, Gwathmey JK, Briggs GM, Morgan JP. Differential effect of DPI 201-106 on the sensitivity of the myofilaments to Ca2+ in intact and skinned trabeculae from control and myopathic human hearts. J Clin Invest 1988; 82:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/69\">",
"      Wankerl M, B&ouml;hm M, Morano I, et al. Calcium sensitivity and myosin light chain pattern of atrial and ventricular skinned cardiac fibers from patients with various kinds of cardiac disease. J Mol Cell Cardiol 1990; 22:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/70\">",
"      D'Agnolo A, Luciani GB, Mazzucco A, et al. Contractile properties and Ca2+ release activity of the sarcoplasmic reticulum in dilated cardiomyopathy. Circulation 1992; 85:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/71\">",
"      Lowe JE, Jennings RB, Reimer KA. Cardiac rigor mortis in dogs. J Mol Cell Cardiol 1979; 11:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/72\">",
"      Lamb HJ, Beyerbacht HP, van der Laarse A, et al. Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism. Circulation 1999; 99:2261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/73\">",
"      Apstein CS, Deckelbaum L, Hagopian L, Hood WB Jr. Acute cardiac ischemia and reperfusion: contractility, relaxation, and glycolysis. Am J Physiol 1978; 235:H637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/74\">",
"      Apstein CS, Gravino FN, Haudenschild CC. Determinants of a protective effect of glucose and insulin on the ischemic myocardium. Effects on contractile function, diastolic compliance, metabolism, and ultrastructure during ischemia and reperfusion. Circ Res 1983; 52:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/75\">",
"      Schaefer S, Prussel E, Carr LJ. Requirement of glycolytic substrate for metabolic recovery during moderate low flow ischemia. J Mol Cell Cardiol 1995; 27:2167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/76\">",
"      Vanoverschelde JL, Janier MF, Bakke JE, et al. Rate of glycolysis during ischemia determines extent of ischemic injury and functional recovery after reperfusion. Am J Physiol 1994; 267:H1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/77\">",
"      Kagaya Y, Weinberg EO, Ito N, et al. Glycolytic inhibition: effects on diastolic relaxation and intracellular calcium handling in hypertrophied rat ventricular myocytes. J Clin Invest 1995; 95:2766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/78\">",
"      Tian R, Nascimben L, Ingwall JS, Lorell BH. Failure to maintain a low ADP concentration impairs diastolic function in hypertrophied rat hearts. Circulation 1997; 96:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/79\">",
"      Cunningham MJ, Apstein CS, Weinberg EO, et al. Influence of glucose and insulin on the exaggerated diastolic and systolic dysfunction of hypertrophied rat hearts during hypoxia. Circ Res 1990; 66:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/80\">",
"      Weiss J, Hiltbrand B. Functional compartmentation of glycolytic versus oxidative metabolism in isolated rabbit heart. J Clin Invest 1985; 75:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/81\">",
"      Cunningham MJ, Apstein CS, Weinberg EO, Lorell BH. Deleterious effect of ouabain on myocardial function during hypoxia. Am J Physiol 1989; 256:H681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/82\">",
"      Lorell BH, Isoyama S, Grice WN, et al. Effects of ouabain and isoproterenol on left ventricular diastolic function during low-flow ischemia in isolated, blood-perfused rabbit hearts. Circ Res 1988; 63:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/83\">",
"      Weinberg, EO, Apstein, CS, Vogel, WM. Impaired myocardial relaxation is improved by combined beta-adrenergic stimulation and calcium channel blockade. J Mol Cell Cardiol 1991; 23:S68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/84\">",
"      Raman VK, Lee YA, Lindpaintner K. The cardiac renin-angiotensin-aldosterone system and hypertensive cardiac hypertrophy. Am J Cardiol 1995; 76:18D.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/85\">",
"      Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993; 153:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/86\">",
"      Schunkert H, Dzau VJ, Tang SS, et al. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. J Clin Invest 1990; 86:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/87\">",
"      Eberli FR, Apstein CS, Ngoy S, Lorell BH. Exacerbation of left ventricular ischemic diastolic dysfunction by pressure-overload hypertrophy. Modification by specific inhibition of cardiac angiotensin converting enzyme. Circ Res 1992; 70:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/88\">",
"      Helmes M, Trombit&aacute;s K, Granzier H. Titin develops restoring force in rat cardiac myocytes. Circ Res 1996; 79:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/89\">",
"      Helmes M, Lim CC, Liao R, et al. Titin determines the Frank-Starling relation in early diastole. J Gen Physiol 2003; 121:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/90\">",
"      Cheng CP, Noda T, Nozawa T, Little WC. Effect of heart failure on the mechanism of exercise-induced augmentation of mitral valve flow. Circ Res 1993; 72:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/38/30313/abstract/91\">",
"      Gerull B, Gramlich M, Atherton J, et al. Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nat Genet 2002; 30:201.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3463 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-7484D81656-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_38_30313=[""].join("\n");
var outline_f29_38_30313=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30857764\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EXCITATION-CONTRACTION AND REPOLARIZATION-RELAXATION COUPLING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Role of calcium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cyclic AMP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other second messengers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mechanisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ABNORMAL CALCIUM MODULATION IN HEART DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Systole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diastole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SARCOLEMMAL RECEPTORS AND MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Adrenergic receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Calcium binding sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Sodium-calcium exchange",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Calcium ATPase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Sarcoplasmic reticulum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ALTERED MYOFILAMENT CALCIUM RESPONSIVENESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ALTERATION OF EXCITATION-CONTRACTION AND REPOLARIZATION-RELAXATION COUPLING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Role of adenosine triphosphate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Role of glycolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Digitalis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Beta-adrenergic stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Role of angiotensin II and angiotensin converting enzyme inhibition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      ROLE OF TITIN IN DIASTOLIC FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30857764\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3463\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3463|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?6/34/6702\" title=\"algorithm 1\">",
"      Cell mechanism diastol dysfunct",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3463|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/34/21025\" title=\"figure 1\">",
"      Regulation sarcolemma function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/21/14673\" title=\"figure 2\">",
"      Troponin tropomyosin complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/50/6948\" title=\"figure 3\">",
"      Changes calcium sensitivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/39/39549\" title=\"figure 4\">",
"      Excitation contraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/14/27886\" title=\"figure 5\">",
"      Regulation contractile state",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/31/19966\" title=\"figure 6\">",
"      Phosphatidylinositol turnover",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/14/8417\" title=\"figure 7\">",
"      Regulation SR function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/7/15487\" title=\"figure 8\">",
"      Contraction relaxation cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/40/19074\" title=\"figure 9\">",
"      Actin myosin interaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3463|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/63/6141\" title=\"table 1\">",
"      Interventions intracell calcium",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36825?source=related_link\">",
"      Actions of angiotensin II on the heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14008?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in heart failure: Mechanisms of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=related_link\">",
"      Clinical manifestations and diagnosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10632?source=related_link\">",
"      Excitation-contraction coupling in myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=related_link\">",
"      Genetics of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15818?source=related_link\">",
"      Pathophysiology of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_38_30314="AITL CD3";
var content_f29_38_30314=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F86424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F86424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Angioimmunoblastic T cell lymphoma around high endothelial venules",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CD3 stain, immunoperoxidase, x20.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sun T. Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_38_30314=[""].join("\n");
var outline_f29_38_30314=null;
var title_f29_38_30315="FIST violence screening";
var content_f29_38_30315=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    FISTS violence screening questions for adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Fights: How many fights have you been in in the past year? When was your last fight?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Teens who have been in more than one physical fight in the preceding 12 months are at increased risk of violence-related injury.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Injuries: Have you ever been injured in a fight? Have you ever injured anyone else?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple",
"or serious previous injuries may indicate an increased risk of future",
"injury. Patients who have been injured may be more likely to carry",
"weapons.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Sexual violence: What happens when you and your boyfriend/girlfriend fight? Have you ever had sex against your will?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Teen-dating violence is associated with future domestic violence.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Threats: Have you ever been threatened?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Teenagers who have been threatened with a weapon are at future risk of weapons-related injury.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Self-defense: Have you ever carried a weapon to protect yourself?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Teenagers who arm themselves in self-defense are at increased risk for violence-related injury.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Alpert E, Sege R, Bradshaw Y. Academic Medicine 1997; 72 (suppl):S41.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_38_30315=[""].join("\n");
var outline_f29_38_30315=null;
var title_f29_38_30316="Technique and findings with a digital rectal examination";
var content_f29_38_30316=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Components of the technique and expected findings with a detailed digital rectal examination",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Exam component",
"       </td>",
"       <td class=\"subtitle1\">",
"        Technique",
"       </td>",
"       <td class=\"subtitle1\">",
"        Findings and grading of response(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         I. Inspection of the anus and surrounding tissue",
"        </strong>",
"       </td>",
"       <td>",
"        Place patient in the left lateral position with hips flexed to 90&deg;. Inspect perineum under good light.",
"       </td>",
"       <td>",
"        Skin excoriation, skin tags, anal fissure, scars or hemorrhoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         II. Testing of perineal sensation and the anocutaneous reflex",
"        </strong>",
"       </td>",
"       <td>",
"        Stroke the skin around the anus in a centripetal fashion, in all four quadrants, by using a stick with a cotton bud",
"       </td>",
"       <td>",
"        <p>",
"         Normal: Brisk contraction of the perianal skin, the anoderm and the external anal sphincter",
"        </p>",
"        <p>",
"         Impaired: No response with the soft cotton bud, but anal contractile response seen with the opposite (wooden) end",
"        </p>",
"        <p>",
"         Absent: No response with either end",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        III. Digital palpation and maneuvers to assess anorectal function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Digital palpation",
"       </td>",
"       <td>",
"        Slowly advance a lubricated and gloved index finger into the rectum and feel the mucosa and surrounding muscle, bone, uterus, prostate and pelvic structures",
"       </td>",
"       <td>",
"        Tenderness, mass, stricture, or stool and the consistency of the stool",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Resting tone",
"       </td>",
"       <td>",
"        Assess strength of resting sphincter tone",
"       </td>",
"       <td>",
"        Normal, weak (decreased), or increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Squeeze maneuver",
"       </td>",
"       <td>",
"        Ask the patient to squeeze and hold as long as possible (up to 30 seconds)",
"       </td>",
"       <td>",
"        Normal, weak (decreased), or increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pushing and bearing down maneuver",
"       </td>",
"       <td>",
"        In addition to the finger in the rectum, place a hand over the patient's abdomen to assess the push effort. Ask the patient to push and bear down as if to defecate.",
"       </td>",
"       <td>",
"        <ol>",
"         <li>",
"          Push effort: Normal, weak (decreased), excessive",
"         </li>",
"         <li>",
"          Anal relaxation: Normal, impaired, paradoxical contraction",
"         </li>",
"         <li>",
"          Perineal descent: Normal, excessive, absent",
"         </li>",
"        </ol>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Tantiphlachiva K, Rao P, Attaluri A, Rao SSC. Digital rectal examination is a useful tool for identifying patients with dyssynergia. Clin Gastroenterol Hepatol 2010; 8:955. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_38_30316=[""].join("\n");
var outline_f29_38_30316=null;
var title_f29_38_30317="Percent LDL reduction outcome";
var content_f29_38_30317=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    No correlation between percent LDL-cholesterol reduction and event rate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 287px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In 6595 men with elevated serum LDL-cholesterol and no clinical evidence of coronary artery disease entered into the WOSCOPS trial, there was no obvious relationship between the degree of LDL-cholesterol reduction with pravastatin and the risk of a cardiovascular event during a 4.4 year follow-up. A 24 percent reduction in LDL-cholesterol was sufficient to produce the full benefit from pravastatin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from West of Scotland Coronary Prevention Study Group, Circulation 1998; 97:1440.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_38_30317=[""].join("\n");
var outline_f29_38_30317=null;
var title_f29_38_30318="Contrast study in duodenal atresia";
var content_f29_38_30318=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Contrast study in duodenal atresia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Contrast study of the upper gastrointestinal tract demonstrates dilation of the stomach and proximal duodenum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_38_30318=[""].join("\n");
var outline_f29_38_30318=null;
var title_f29_38_30319="Forearm extensor stretch PI";
var content_f29_38_30319=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F65485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F65485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Forearm extensor stretch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hold your injured arm straight out in front of you, palm down, with your fingers pointing toward the ground. Use your other hand to grab the hand on the injured side, pressing your thumb into the palm. Then press down on the back of the hand on the injured side so that your wrist bends further than it does on its own. Hold this position for 30 seconds.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_38_30319=[""].join("\n");
var outline_f29_38_30319=null;
